US 8,626,255 B2Grant

Noninvasive multi-parameter patient monitor

Issue Date:2014-01-07

•15 Claims

•19 Drawing Sheets

Abstract

Embodiments of the present disclosure include a handheld multi-parameter patient monitor capable of determining multiple physiological parameters from the output of a light sensitive detector capable of detecting light attenuated by body tissue. For example, in an embodiment, the monitor is capable of advantageously and accurately displaying one or more of pulse rate, plethysmograph data, perfusion quality, signal confidence, and values of blood constituents in body tissue, including for example, arterial carbon monoxide saturation (“HbCO”), methemoglobin saturation (“HbMet”), total hemoglobin (“Hbt”), arterial oxygen saturation (“SpO₂”), fractional arterial oxygen saturation (“SpaO₂”), or the like. In an embodiment, the monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display real estate.

Metadata

Assignee

Cercacor Laboratories, Inc.

Inventors

Ammar Al-Ali
Joe E. Kiani
Mohamed K. Diab
Greg A. Olsen
Roger C. Wu
Rick Fishel

Application Information

Application Number:US 13/477,979

Filing Date:2012-05-22

Priority Date:2005-03-01

Art Unit:3777

Classifications

IPC:

A61B5/1455

Patent Drawings (19 sheets)

Description

Priority Claim to Related Provisional Applications

[0001] The present application is a continuation of U.S. patent application Ser. No. 11/367,033, filed Mar. 1, 2006, which claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 60/657,596, filed Mar. 1, 2005, entitled “Multiple Wavelength Sensor,” No. 60/657,281, filed Mar. 1, 2005, entitled “Physiological Parameter Confidence Measure,” No. 60/657,268, filed Mar. 1, 2005, entitled “Configurable Physiological Measurement System,” and No. 60/657,759, filed Mar. 1, 2005, entitled “Noninvasive Multi-Parameter Patient Monitor.” The present application incorporates the foregoing disclosures herein by reference.

Incorporation by Reference of Related Utility Applications

[0002] The present application is related to the following copending U.S. utility applications:

[0003]


	App.
	Sr. No.	Filing Date	Title	Atty Dock.


1	11/367,013	Mar. 1, 2006	Multiple Wavelength	MLR.002A
			Sensor Emitters
2	11/366,995	Mar. 1, 2006	Multiple Wavelength	MLR.003A
			Sensor Equalization
3	11/366,209	Mar. 1, 2006	Multiple Wavelength	MLR.004A
			Sensor Substrate
4	11/366,210	Mar. 1, 2006	Multiple Wavelength	MLR.005A
			Sensor Interconnect
5	11/366,833	Mar. 1, 2006	Multiple Wavelength	MLR.006A
			Sensor Attachment
6	11/366,997	Mar. 1, 2006	Multiple Wavelength	MLR.009A
			Sensor Drivers
7	11/367,034	Mar. 1, 2006	Physiological Parameter	MLR.010A
			Confidence Measure
8	11/367,036	Mar. 1, 2006	Configurable	MLR.011A
			Physiological
			Measurement System
9	11/367,033	Mar. 1, 2006	Noninvasive Multi-	MLR.012A
			Parameter Patient
			Monitor
10	11/367,014	Mar. 1, 2006	Noninvasive Multi-	MLR.013A
			Parameter Patient
			Monitor
11	11/366,208	Mar. 1, 2006	Noninvasive Multi-	MLR.014A
			Parameter Patient
			Monitor
12	13/412,428	Mar. 5, 2012	Noninvasive Multi-	MLR.014C1
			Parameter Patient
			Monitor
13	12/949,271	Nov. 18,	Physiological	MLR.018A
		2010	Measurement System
			with Automatic
			Wavelength Adjustment

[0004] The present application incorporates the foregoing disclosures herein by reference.

Field of the Disclosure

[0005] The present disclosure relates to the field of noninvasive patient monitors. More specifically, the disclosure relates to monitors displaying measurements derived using signals from optical sensors.

Background

[0006] Spectroscopy is a common technique for measuring the concentration of organic and some inorganic constituents of a solution. The theoretical basis of this technique is the Beer-Lambert law, which states that the concentration c_iof an absorbent in solution can be determined by the intensity of light transmitted through the solution, knowing the pathlength d_λ, the intensity of the incident light I_0,λ, and the extinction coefficient ε_i,λ at a particular wavelength λ. In generalized form, the Beer-Lambert law is expressed as:
I_λ=I_0,λe^−d^λ^·μ^0,λ (1)

[0007]

\begin{matrix} μ_{0, λ} = \sum_{i = 1}^{n} ɛ_{i, λ} \cdot c_{i} & (2) \end{matrix}

[0008] where μ_0,λ is the bulk absorption coefficient and represents the probability of absorption per unit length. The minimum number of discrete wavelengths that are required to solve Equations 1-2 are the number of significant absorbers that are present in the solution.

[0009] A practical application of this technique is pulse oximetry, which utilizes a noninvasive sensor to measure oxygen saturation (SpO₂) and pulse rate. In general, the sensor has light emitting diodes (LEDs) that transmit optical radiation of red and infrared wavelengths into a tissue site and a detector that responds to the intensity of the optical radiation after absorption (e.g., by transmission or transreflectance) by pulsatile arterial blood flowing within the tissue site. Based on this response, a processor determines measurements for SpO₂, pulse rate, and can output representative plethysmographic waveforms. Thus, “pulse oximetry” as used herein encompasses its broad ordinary meaning known to one of skill in the art, which includes at least those noninvasive procedures for measuring parameters of circulating blood through spectroscopy. Moreover, “plethysmograph” as used herein (commonly referred to as “photoplethysmograph”), encompasses its broad ordinary meaning known to one of skill in the art, which includes at least data representative of a change in the absorption of particular wavelengths of light as a function of the changes in body tissue resulting from pulsing blood.

[0010] Pulse oximeters capable of reading through motion induced noise are available from Masimo Corporation (“Masimo”) of Irvine, Calif. Moreover, portable and other oximeters capable of reading through motion induced noise are disclosed in at least U.S. Pat. Nos. 6,770,028, 6,658,276, 6,157,850, 6,002,952, and 5,769,785. Read which are owned by Masimo, and are incorporated by reference herein. Such reading through motion oximeters have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.

Summary of the Disclosure

[0011] Despite the success of read through motion oximeter systems, there is a need to provide patient monitors capable of displaying multiple physiological parameters, other than or in addition to SpO₂, plethysmograph waveforms, or pulse rates. For example, in accessing a patient's condition, caregivers often desire knowledge of other blood constituents, including for example, a percent value for arterial carbon monoxide saturation (“HbCO”) or a percent value for methemogobin saturation (“HbMet”) or the like. For example, in an embodiment, the display advantageously displays one or more of the following: pulse rate, plethysmograph waveform data, perfusion index, values of blood constituents in body tissue, including for example, HbCO, HbMet, total hemoglobin (“Hbt”), arterial oxygen saturation (“SpO₂”), fractional arterial oxygen saturation (“SpaO₂”), or the like. In other embodiments, the monitor may advantageously and accurately determine values for one or more of HbO₂, Hb, blood glucose, water, the presence or absence of therapeutic drugs (aspirin, Dapson, nitrates, or the like) or abusive/recreational drugs (methamphetamine, alcohol, steroids, or the like), concentrations of carbon dioxide (“CO₂”) or oxygen (“O”), ph levels, bilirubin, perfusion quality, signal quality or the like. Accordingly, the present disclosure includes a multi-parameter patient monitor capable of determining one or more of the foregoing parameters, other than or in addition to, SpO₂, plethysmograph waveforms, or perfusion quality index.

[0012] In an embodiment, the display of a noninvasive multi-parameter patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display area or real estate. In an embodiment, a user may cycle different parameter values through an area of the display common to both parameters even when one parameter is shifted, through, for example, actuation of a user input key. The patient monitor may also display different parameters as color-coded. For example, when the following measured parameters are within “normal” ranges, SpO₂may be displayed red, pulse rate (BPM) may be displayed green, HbCO may be displayed orange, HbMet may be displayed blue, or the like. In an embodiment, measured values of SpO₂may be displayed in white, BPM may be displayed in yellow green or aquamarine, PI™ may be displayed in violet, Hbt may be displayed in grass green, HbMet may be displayed in blue or light blue, HbCO may be displayed in orange, and SpaO₂may be displayed in electric blue.

[0013] Moreover, parameter trend data may also be displayed using the same or similar color coding, especially when multiple trends are displayed on one or more display graphs. In addition, more coarse or gross parameter indications may be displayed for quick reference to indicate to a caregiver whether any of a variety of monitored parameters, such as, for example, SpO₂, HbCO or HbMet is within acceptable ranges. The monitor may advantageously include additional display information, such as, for example, parametric displays where one parameter is displayed as a function of another, three dimensional displays (for example, extending a parametric display along time or an additional parameter), directional indicators predicting where a parameter is likely heading or reporting a general direction a parameters has been trending, or the like.

[0014] In addition to the foregoing, caregivers often desire to more closely monitor parameters that are close to, approaching, or beyond normal safe thresholds. In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical monitored parameters. In alternative embodiments, the patient monitor automatically changes display modes to show parameters moving closer to or beyond normal thresholds.

[0015] In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the monitor may determine how many wavelengths a particular attached sensor will emit through communication with memory devices associated with the attached sensor or cable.

[0016] Additional embodiments include audio or visual alarms for each of multiple monitored parameters, combinations of parameters, an indication of perfusion in the tissue of the measurement site, an indication of the confidence the signal processing has in its output measurements, or the like.

[0017] For purposes of summarization, certain aspects, advantages and novel features are described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features need to be present in any particular embodiment.

Brief Description of the Drawings

[0018] The drawings and the associated descriptions are provided to illustrate embodiments of the disclosure and not to limit the scope of the claims.

[0019] FIG. 1 illustrates a block diagram of an exemplary embodiment of a patient monitoring system including a sensor and a multi-parameter patient monitor.

[0020] FIG. 2 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO, such as, for example, the patient monitor of FIG. 1.

[0021] FIG. 3 illustrates an exemplary display of the patient monitor of FIG. 2.

[0022] FIG. 4 illustrates the display of FIG. 3 showing measured values of SpO₂, BPM, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

[0023] FIG. 5 illustrates the display of FIG. 3 showing measured values of HbCO, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

[0024] FIG. 6 illustrates the display of FIG. 3 showing measured values of SpO₂, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1.

[0025] FIG. 7 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 1.

[0026] FIG. 8 illustrates an exemplary display of the patient monitor of FIG. 7.

[0027] FIG. 9 illustrates the display of FIG. 8 showing measured values of SpO₂, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

[0028] FIG. 10 illustrates the display of FIG. 8 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

[0029] FIG. 11A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor such as, for example, the patient monitor of FIG. 1.

[0030] FIGS. 11B-11H illustrate display screens of the patient monitor of FIG. 11A.

Detailed Description of Preferred and Alternative Embodiments

[0031] Embodiments of the present disclosure include a portable or other multi-parameter patient monitor capable of determining multiple physiological parameters from one or more signals output from one or more light sensitive detectors capable of detecting light attenuated by body tissue carrying pulsing blood. For example, in an embodiment, the monitor advantageously and accurately determines a wide variety of physiological parameters or other calculations as discussed above.

[0032] In an embodiment, the display of patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display real estate. For example, the patient monitor may include one or more user input keys capable of toggling through measurement data. In an embodiment, the displays include mode indicators providing caregivers easily identifiable visual queues, such as LED's, text, icons, or other indicia providing readily identifiable queues as to which parameter is being displayed. In an embodiment, the display may shift, may be parameter color-coded, or the like to further ensure quick comprehension of which measured parameter is the displayed parameter. For example, in an embodiment, the monitor displays SpO₂in white, pulse rate (BPM) in green, HbCO in orange, and HbMet in blue when the respective measured parameter is within a “normal” range.

[0033] In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical or time sensitive measured parameters, specific caregiver selected parameters, or the like. For example, the patient monitor may advantageously sound audio or visual alarms that alert the caregiver to particular one or more of worsening parameters, parameters changing in a predetermined pattern or rate, parameters stabilizing below user defined or safe thresholds, caregiver selected parameters, or the like. The monitor may also use alerts that provide audio or visual indications of the severity of the condition, severity of the change, or the like. In alternative embodiments, the patient monitor may automatically change display modes when a particular parameter crosses one or more thresholds. For example, a patient monitor may be displaying a first parameter, such as a plethysmograph, and upon determining measurements indicating that HBMet is trending toward an alarm condition, the monitor may automatically switch from displaying the first parameter to the alarming parameter, or in this case, a trend of the alarming parameter.

[0034] In an embodiment, a switch is provided to allow a user to switch displays to view an alarming measurement. In an embodiment, during an alarm condition, a parameter display may switch to a trend graph in the same or different color, line weight, flash, flash rate, intensity, size, or the like.

[0035] The patient monitor may also include one or more displays capable of displaying trend data for any one or more of the monitored or derived patient parameters. For example, the trend data may be displayed in graph form, may include multiple trend lines, each representing a different monitored or derived patient parameter. Moreover, each trend line may be color-coded to facilitate quick comprehension of which trend line represents which measured parameter. However, an artisan will recognize from the disclosure herein a large number of identification techniques including color-coding, identifying text, or the like. Additionally, user input may toggle displayed trend data, may select which parameters to display simultaneously, or the like.

[0036] In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the patient monitor may provide a particular audio or visual indication, such as a beep, LED activation, graphic activation, text messages, voice messages, or the like, to indicate communication with or connection to an approved sensor, patient cable, combination, or the like. In an embodiment, the indication may change based on the manufacturer, type of sensor recognized or not recognized, type of patient, type of physiological parameters measurable with the attached sensor, or the like. Additional embodiments include an indication of perfusion in the tissue of the measurement site and an indication of the confidence the signal processing has in its output measurements or input signal quality.

[0037] To facilitate an understanding of the disclosure, the remainder of the description references exemplary embodiments illustrated in the drawings. Moreover, in this application, reference is made to many blood parameters. Some references that have common shorthand designations are referenced through such shorthand designations. For example, as used herein, HbCO designates carboxyhemoglobin, HbMet designates methemoglobin, and Hbt designates total hemoglobin. Other shorthand designations such as COHb, MetHb, and tHb are also common in the art for these same constituents. These constituents are generally reported herein in terms of a percentage, often referred to as saturation, relative concentration or fractional saturation. Total hemoglobin is generally reported as a concentration in g/dL. The use of the particular shorthand designators presented in this application does not restrict the term to any particular manner in which the designated constituent is reported.

[0038] FIG. 1 illustrates a block diagram of an exemplary embodiment of a patient monitoring system 100. As shown in FIG. 1, the system 100 includes a patient monitor 102 comprising a processing board 104 and a host instrument 108. The processing board 104 communicates with a sensor 106 to receive one or more intensity signal(s) indicative of one or more parameters of tissue of a patient. The processing board 104 also communicates with a host instrument 108 to display determined values calculated using the one or more intensity signals. According to an embodiment, the board 104 comprises processing circuitry arranged on one or more printed circuit boards capable of installation into the monitor 102, or capable of being distributed as some or all of one or more OEM components for a wide variety of host instruments monitoring a wide variety of patient information. In an embodiment, the processing board 102 comprises a sensor interface 110, a digital signal processor and signal extractor (“DSP” or “processor”) 112, and an instrument manager 114. In general, the sensor interface 110 converts digital control signals into analog drive signals capable of driving sensor emitters, and converts composite analog intensity signal(s) from light sensitive detectors into digital data.

[0039] In an embodiment, the sensor interface 110 manages communication with external computing devices. For example, in an embodiment, a multipurpose sensor port (or input/output port) is capable of connecting to the sensor 106 or alternatively connecting to a computing device, such as a personal computer, a PDA, additional monitoring equipment or networks, or the like. When connected to the computing device, the processing board 104 may upload various stored data for, for example, off-line analysis and diagnosis. The stored data may comprise trend data for any one or more of the measured parameter data, plethysmograph waveform data acoustic sound waveform, or the like. Moreover, the processing board 104 may advantageously download from the computing device various upgrades or executable programs, may perform diagnosis on the hardware or software of the monitor 102. In addition, the processing board 104 may advantageously be used to view and examine patient data, including raw data, at or away from a monitoring site, through data uploads/downloads, or network connections, combinations, or the like, such as for customer support purposes including software maintenance, customer technical support, and the like. Upgradable sensor ports are disclosed in copending U.S. application Ser. No. 10/898,680, filed on Jul. 23, 2004, titled “Multipurpose Sensor Port,” incorporated by reference herein.

[0040] As shown in FIG. 1, the digital data is output to the DSP 112. According to an embodiment, the DSP 112 comprises a processing device based on the Super Harvard ARChitecture (“SHARC”), such as those commercially available from Analog Devices. However, a skilled artisan will recognize from the disclosure herein that the DSP 112 can comprise a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In particular, the DSP 112 includes program instructions capable of receiving multiple channels of data related to one or more intensity signals representative of the absorption (from transmissive or reflective sensor systems) of a plurality of wavelengths of emitted light by body tissue. In an embodiment, the DSP 112 accepts data related to the absorption of eight (8) wavelengths of light, although an artisan will recognize from the disclosure herein that the data can be related to the absorption of two (2) to sixteen (16) or more wavelengths.

[0041] FIG. 1 also shows the processing board 104 including the instrument manager 114. According to an embodiment, the instrument manager 114 may comprise one or more microcontrollers controlling system management, including, for example, communications of calculated parameter data and the like to the host instrument 108. The instrument manager 114 may also act as a watchdog circuit by, for example, monitoring the activity of the DSP 112 and resetting it when appropriate.

[0042] The sensor 106 may comprise a reusable clip-type sensor, a disposable adhesive-type sensor, a combination sensor having reusable and disposable components, or the like. Moreover, an artisan will recognize from the disclosure herein that the sensor 106 can also comprise mechanical structures, adhesive or other tape structures, Velcro wraps or combination structures specialized for the type of patient, type of monitoring, type of monitor, or the like. In an embodiment, the sensor 106 provides data to the board 104 and vice versa through, for example, a patient cable. An artisan will also recognize from the disclosure herein that such communication can be wireless, over public or private networks or computing systems or devices, or the like.

[0043] As shown in FIG. 1, the sensor 106 includes a plurality of emitters 116 irradiating the body tissue 118 with differing wavelengths of light, and one or more detectors 120 capable of detecting the light after attenuation by the tissue 118. In an embodiment, the emitters 116 comprise a matrix of eight (8) emission devices mounted on a flexible substrate, the emission devices being capable of emitting eight (8) differing wavelengths of light. In other embodiments, the emitters 116 may comprise twelve (12) or sixteen (16) emitters, although other numbers of emitters are contemplated, including two (2) or more emitters. As shown in FIG. 1, the sensor 106 may include other electrical components such as, for example, a memory device 122 comprising an EPROM, EEPROM, ROM, RAM, microcontroller, combinations of the same, or the like. In an embodiment, other sensor components may include a temperature determination device 123 or other mechanisms for, for example, determining real-time emission wavelengths of the emitters 116.

[0044] The memory 122 may advantageous store some or all of a wide variety data and information, including, for example, information on the type or operation of the sensor 106; type or identification of sensor buyer or distributor or groups of buyer or distributors, sensor manufacturer information, sensor characteristics including the number of emitting devices, the number of emission wavelengths, data relating to emission centroids, data relating to a change in emission characteristics based on varying temperature, history of the sensor temperature, current, or voltage, emitter specifications, emitter drive requirements, demodulation data, calculation mode data, the parameters for which the sensor is capable of supplying sufficient measurement data (e.g., HpCO, HpMet, HbT, or the like), calibration or parameter coefficient data, software such as scripts, executable code, or the like, sensor electronic elements, whether the sensor is a disposable, reusable, multi-site, partially reusable, partially disposable sensor, whether it is an adhesive or non-adhesive sensor, whether the sensor is a reflectance, transmittance, or transreflectance sensor, whether the sensor is a finger, hand, foot, forehead, or ear sensor, whether the sensor is a stereo sensor or a two-headed sensor, sensor life data indicating whether some or all sensor components have expired and should be replaced, encryption information, keys, indexes to keys or hash functions, or the like, monitor or algorithm upgrade instructions or data, some or all of parameter equations, information about the patient, age, sex, medications, and other information that may be useful for the accuracy or alarm settings and sensitivities, trend history, alarm history, or the like. In an embodiment, the monitor may advantageously store data on the memory device, including, for example, measured trending data for any number of parameters for any number of patients, or the like, sensor use or expiration calculations, sensor history, or the like.

[0045] FIG. 1 also shows the patient monitor 102 including the host instrument 108. In an embodiment, the host instrument 108 communicates with the board 104 to receive signals indicative of the physiological parameter information calculated by the DSP 112. The host instrument 108 preferably includes one or more display devices 124 capable of displaying indicia representative of the calculated physiological parameters of the tissue 118 at the measurement site. In an embodiment, the host instrument 108 may advantageously comprise a handheld housing capable of displaying one or more of a pulse rate, plethysmograph data, perfusion quality such as a perfusion quality index (“PI™”), signal or measurement quality (“SQ”), values of blood constituents in body tissue, including for example, SpO₂, HbCO, HbMet, Hbt, or the like. In other embodiments, the host instrument 108 is capable of displaying values for one or more of Hbt, Hb, blood glucose, bilirubin, or the like. The host instrument 108 may be capable of storing or displaying historical or trending data related to one or more of the measured values, combinations of the measured values, plethysmograph data, or the like. The host instrument 108 also includes an audio indicator 126 and user input device 128, such as, for example, a keypad, touch screen, pointing device, voice recognition device, or the like.

[0046] In still additional embodiments, the host instrument 108 includes audio or visual alarms that alert caregivers that one or more physiological parameters are falling below predetermined safe thresholds. The host instrument 108 may include indications of the confidence a caregiver should have in the displayed data. In a further embodiment, the host instrument 108 may advantageously include circuitry capable of determining the expiration or overuse of components of the sensor 106, including, for example, reusable elements, disposable elements, or combinations of the same.

[0047] Although described in terms of certain embodiments, other embodiments or combination of embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 102 may comprise one or more monitoring systems monitoring parameters, such as, for example, vital signs, blood pressure, ECG or EKG, respiration, glucose, bilirubin, or the like. Such systems may combine other information with intensity-derived information to influence diagnosis or device operation. Moreover, the monitor 102 may advantageously include an audio system, preferably comprising a high quality audio processor and high quality speakers to provide for voiced alarms, messaging, or the like. In an embodiment, the monitor 102 may advantageously include an audio out jack, conventional audio jacks, headphone jacks, or the like, such that any of the display information disclosed herein may be audiblized for a listener. For example, the monitor 102 may include an audible transducer input (such as a microphone, piezoelectric sensor, or the like) for collecting one or more of heart sounds, lung sounds, trachea sounds, or other body sounds and such sounds may be reproduced through the audio system and output from the monitor 102. Also, wired or wireless communications (such as Bluetooth or WiFi, including IEEE 801.11a, b, or g), mobile communications, combinations of the same, or the like, may be used to transmit the audio output to other audio transducers separate from the monitor 102.

[0048] For example, patterns or changes in the continuous noninvasive monitoring of intensity-derived information may cause the activation of other vital sign measurement devices, such as, for example, blood pressure cuffs.

[0049] FIG. 2 illustrates a perspective view of an exemplary handheld noninvasive multi-parameter patient monitor 200, such as, for example, the patient monitor 102 of FIG. 2. Patient monitors 200 exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name “Rad 57c.” As shown in FIG. 1, the monitor 200 includes a patient cable connector 202 capable of mechanical mating with a patient cable to establish communication between the board 104 and the sensor 106. In an embodiment, the connector 202 comprises a multipurpose cable connector such as that disclosed in the incorporated U.S. application Ser. No. 10/898,680, titled “Multipurpose Sensor Port,” disclosing communication between the board 104 and an external computing device.

[0050] The monitor 202 also comprises a HbCO indicator 204 advantageously providing a visual queue that a HbCO capable sensor is properly connected through the connector 202. For example, the HbCO indicator 204 may advantageously activate when a sensor is connected that communicates sufficient information to determine HbCO, such as, for example, a sensor capable of emitting sufficient different wavelengths of light, a sensor storing sufficient data on the memory 122, a sensor having appropriate encryption data or key, combinations of the same, or the like. For example, in an embodiment, the processor 112 may receive information from a memory 122 indicating a number of available LED wavelengths for the attached sensor. Based on the number of wavelengths, or other information stored on the memory 122, the processor 112 may determine whether an HbCO-ready sensor has been attached to the monitor 200. An artisan will also recognize from the disclosure herein that the HbCO indicator 204 may advantageously comprise a HbMet indicator, Hbt indicator, or the like, which activates to a predetermined color associated with a parameter, or any color, or deactivates the same, to convey a type of attached sensor. Moreover, the artisan will recognize from the disclosure herein other parameters that may use other sensor components and the monitor 200 may include indicators capable of indicating communication with those types of sensors.

[0051] In an embodiment, the monitor 200 may also audibly indicate the type of sensor connected. For example, the monitor 200 may emit predetermined number or frequency of beeps associated with recognition of a particular sensor, a particular manufacturer, failure to recognize the sensor, or the like. Moreover, the sensor type may be indicative of the componentry, such as, for example, whether the sensor produces sufficient data for the determination of HbCO, HbMet, Hbt and SpO₂, SpO₂only, SpO₂and HbMet, any combination of the foregoing or other parameters, or the like. Additionally, the sensor type may be indicative of specific sensors designed for a type of patient, type of patient tissue, or the like. In other embodiments, the monitor 200 may announce the type of connector through speaker 236.

[0052] An artisan will also recognize from the disclosure herein that other mechanical (such as keys), electrical, or combination devices may inform the monitor 202 of the type of attached sensor. In an embodiment, the processor 112 also may select to drive less emitters that are currently available, such as, for example, in the presence of low noise and when power consumption is an issue.

[0053] The monitor 202 also comprises a multi-mode display 206 capable of displaying, for example, measurements of SpO₂and HbCO (or alternatively, HbMet). In an embodiment, the display 206 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 200. Thus, the multi-mode display 206 may advantageously cycle through two or more measured parameters in an area common to both parameters even when shifted. In such embodiments, the monitor 200 may also advantageously include parameter indicators 208, 210, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 206 displays measured values of SpO₂that are normal, the numbers may advantageously appear in green, while normal measured values of HbCO may advantageously appear in orange, and normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 206 flashes at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.

[0054] The monitor 202 also comprises a HbCO bar 212 where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value. For example, the bar 212 is lowest when the dangers from carbon monoxide poisoning are the least, and highest when the dangers are the greatest. The bar 212 includes indicia 214 that provide an indication of the severity of carbon monoxide saturation in a patient's blood. As shown in FIG. 2, the bar 212 and the indicia 214 continuously indicate the concentration of HbCO in about 5% increments. The indicia 214 indicate a measurement of HbCO saturation percentage between about 0 and about 50% with a granularity of about 5%. However, an artisan will also recognize from the disclosure herein a wide variety of ranges and granularities could be used, the indicia 214 could be electronically displayed in order to straightforwardly increase or decrease resolution, or the like. For example, HbCO may advantageously be displayed with greater resolution than ±about %5 in a lower portion of the scale. For example, an HbCO bar may advantageously include a scale of about <3%, about 6%, about 9%, about 12%, about 15%, about 20%, about 25%, about 30%, about 35%, and about >40%.

[0055] As is known in the art, carbon monoxide in the blood can lead to serious medical issues. For example and depending upon the particular physiology of a patient, about 10% carbon monoxide saturation can lead to headaches, about 20% can lead to throbbing headaches, or dyspnea on exertion, about 30% can lead to impaired judgment, nausea, dizziness and/or vomiting, visual disturbance, or fatigue, about 40% can lead to confusion and syncope, and about 50% and above can lead to comas, seizures, respiratory failure and even death.

[0056] In an embodiment, the bar 212 is the same or similar color as the multi-mode display 206 when displaying HbCO. In other embodiments, the bar 212 is lowest and green when the dangers from carbon monoxide poisoning are the least, and highest and red when the dangers are the greatest. In an embodiment, as HbCO increases, the entire bar 212 may advantageously change color, such as, for example, from green to red, to provide a clear indication of deepening severity of the condition. In other embodiments, the bar 212 may advantageously blink or flash, an audio alarm may beep or provide a continuation or rise in pitch or volume, or the like to alert a caregiver of deepening severity. Moreover, straightforward to complex alarm rules may be implemented to reduce false alarms based on, for example, knowledge of the physiological limitations on the rate of change in HbCO or the like.

[0057] Additionally, the monitor 200 may be capable of storing and outputting historical parameter data, display trend traces or data, or the like. Although the foregoing bar 212 has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.

[0058] FIG. 2 also shows the monitor 200 including a pulse display 216 displaying measured pulse rate in beats per minute (“BPM”). In an embodiment, the display 212 flashes when searching for a pulse. The pulse display 216 advantageously displays measured pulse rates from about zero (0) to about two hundred and forty (240) BPM. Moreover, when the measured pulse rates are considered normal, the pulse display 216 is advantageously green. Similar to other displays associated with the monitor 200, the pulse display 216 may employ a variety of color changes, audio alarms, or combinations of the same to indicate measured BPM below predetermined safe thresholds. In an embodiment, the pulse rate display 216 displays the measured pulse rate during the display of SpO₂and displays message data during the display of other parameters. For example, during the display of HbCO, the display 216 may advantageously display the term “CO.” In an embodiment, the display of the message data may be in the same or similar color as the other displays. For example, in an embodiment, the multi-mode display 206, the bar 212, and the pulse display 216 may all display data or messages in orange when the multi-mode display 206 displays measured HbCO values.

[0059] FIG. 2 also illustrates the monitor 200 comprising user input keys 218, including a HbCO button 220, mode/enter button 222, next button 224, power on/off button 226, up/down button 228, and alarm silence button 230. In an embodiment, activation of the HbCO button 220 toggles the measured value displayed in the multi-mode display 206. For example, activation of the HbCO button 220 toggles the multi-mode display 206 from displaying measured values of SpO₂to HbCO for about ten (10) seconds. Activation of the mode/enter button 222 or the next button 224 during the ten (10) second period returns the multi-mode display 206 back to SpO₂. A skilled artisan will also recognize that activation of the HbCO button 220 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO₂, may remain displayed until further activation of the button 220, or the like.

[0060] Activation of the mode/enter button 222 cycles through various setup menus allowing a caregiver to select or activate certain entries within the menu setup system, including alarm threshold customizations, or the like. Activation of the next button 224 can move through setup options within the menu setup system and in an embodiment is not active during normal patient monitoring. For example, a caregiver may activate the mode/enter button 222 and the next button 224 to specify high and low alarm thresholds for one or more of the measured parameters, to specify device sensitivity, trend settings, display customizations, color code parameters, or the like. In an embodiment, the high alarm setting for SpO₂can range from about two percent (2%) to about one hundred percent (100%) with a granularity of about one percent (1%). The low alarm setting for SpO₂can range from about one percent (1%) to about one hundred percent (100%) with a granularity of about one percent (1%). Moreover, the high alarm setting for pulse rate can range from about thirty (30) BPM to about two hundred and forty (240) BPM with a granularity of about five (5) BPM. The low alarm setting for pulse rate can range from about twenty five (25) BPM to about two hundred and thirty five (235) BPM with a granularity of about five (5) BPM. Other high and low ranges for other measured parameters will be apparent to one of ordinary skill in the art from the disclosure herein.

[0061] In a further embodiment, a caregiver may activate the mode/enter button 222 and the next button 224 to specify device sensitivity, such as, for example, device averaging times, probe off detection, whether to enable fast saturation calculations, or the like. Various embodiments of fast saturation calculations are disclosed in U.S. patent application Ser. No. 10/213,270, filed Aug. 5, 2002, titled “Variable Indication Estimator” and incorporated by reference herein. Using the menus, a caregiver may also advantageously enter appropriate information governing trend collection on one or more of the measured parameters, input signals, or the like.

[0062] FIG. 2 also shows the power on/off button 226. Activation of the power on/off button 226 activates and deactivates the monitor 200. In an embodiment, press-and-hold activation for about two (2) seconds shuts the monitor 200 off. In an additional embodiment, activation of the on/off button 226 advantageously initiates detection of a type of attached sensor. For example, activation of the on/off button 226 may advantageously cause the monitor 200 to read information from a memory on an attached sensor and determine whether sufficient wavelengths exist on the sensor to determine one or more the physiological parameters discussed in the foregoing.

[0063] An artisan will recognize from the disclosure herein that the on/off button 226 may advantageously cause an electronic determination of whether to operate in at powers consisted with the U.S. (60 Hz) or another nationality (50 Hz). In an embodiment, such automatic determination and switching is removed from the monitor 200 in order to reduce a likelihood of problematic interfering crosstalk caused by such power switching devices.

[0064] Activation of the up/down button 228 may advantageously adjust the volume of the pulse beep tone. Additionally, activation of the up/down button 228 within the menu setup system, causes the selection of values with various menu options.

[0065] Moreover, activation of the alarm silence button 230 temporarily silences audio alarms for a predetermined period, such as, for example, about one hundred and twenty (120) seconds. A second activation of the alarm silence button 230 mutes (suspends) the alarm indefinitely, while a third activation returns the monitor 200 to standard alarm monitoring. FIG. 2 also shows the alarm silence button 230 includes an alarm silenced indicator 232. The alarm silenced indicator 232 may advantageously flash to indicate one or more alarms are temporarily silenced, may illuminate solid to indicate the alarms have been muted, or the like. Moreover, an artisan will recognize from the disclosure herein a wide variety of alarm silencing methodologies.

[0066] The monitor 202 also includes a battery level indicator 234 indicating remaining battery life. In the illustrated embodiment, four LED's indicate the status of the battery by incrementally deactivating to indicate proportionally decreasing battery life. In an embodiment, the four LED's may also change color as the battery charge decreases, and the final LED may begin to flash to indicate that the caregiver should replace the batteries.

[0067] FIG. 2 also shows the monitor 202 including an audio transducer or speaker 236. The speaker 236 advantageously provides audible indications of alarm conditions, pulse tone and feedback for key-presses, or the like. Moreover, the monitor 202 includes a low signal quality indicator (“SQ” or “SIQ™”) 238. The signal IQ indicator 238 activates to inform a caregiver that a measured value of the quality of the incoming signal is below predetermined threshold values. For example, in an embodiment, the measured value for signal IQ is at least partially based on an evaluation of the plethysmograph data's correspondence to predetermined models or characteristics of physiological signals. In an embodiment, the signal IQ indicator 238 output may be associated with the displayed parameter. For example, the output may be associated with one threshold for the display of SpO₂and another for the display of other parameter data.

[0068] The monitor 202 also comprises a perfusion quality index (“PI™”) bar 240 (which quantifies the measure of perfusion of the patient) where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value. In one embodiment, the PI™ bar 240 shows a static value of perfusion for a given time period, such as, for example, one or more pulses. In another embodiment, or functional setting, the PI™ bar 240 may advantageously pulse with a pulse rate, may hold the last reading and optionally fade until the next reading, may indicate historical readings through colors or fades, or the like. Additionally, the PI™ bar 240 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.

[0069] The PI™ bar 240 can be used to simply indicate inappropriate occlusion due, for example, to improper attachment of the sensor 106. The PI™ bar 240 can also be used as a diagnostic tool during low perfusion for the accurate prediction of illness severity, especially in neonates. Moreover, the rate of change in the PI™ bar 240 can be indicative of blood loss, sleep arousal, sever hypertension, pain management, the presence or absence of drugs, or the like. According to one embodiment, the PI™ bar 240 values may comprise a measurement of the signal strength of the arterial pulse as a percentage of the total signal received. For example, in one preferred embodiment, the alternating portion of at least one intensity signal from the sensor 106 may advantageously be divided by the static portion of the signal. For example, an infrared intensity signal may advantageously be used as it is less subjective to noise.

[0070] In an embodiment, a measurement below about 1.25% may indicate medical situations in need of caregiver attention, specifically in monitored neonates. Because of the relevance of about 1.25%, the PI™ bar 240 may advantageously include level indicia 242 where the indicia 242 swap sides of the PI™ bar 240, thus highlighting any readings below about that threshold. Moreover, behavior of the PI™ bar 240, as discussed above, may advantageously draw attention to monitored values below such a threshold.

[0071] As discussed above, the monitor 200 may include output functionality that outputs, for example, trend perfusion data, such that a caregiver can monitor measured values of perfusion over time. Alternatively or additionally, the monitor 200 may display historical trace data on an appropriate display indicating the measured values of perfusion over time. In an embodiment, the trend data is uploaded to an external computing device through, for example, the multipurpose sensor connector 202 or other input output systems such as USB, serial or parallel ports or the like.

[0072] The monitor 200 also includes an alarm indicator 244 capable of providing visual queues of the status of one or more of the measured parameters. For example, the alarm indicator 244 may advantageously be green when all of the measured parameters are within normal conditions, may gradually fade to red, may flash, increasing flash, or the like, as one or more of the measured values approaches or passes predetermined thresholds. In an embodiment, the alarm indicator 244 activates when any parameter falls below an associated threshold, thereby advantageously informing a caregiver that perhaps a nondisplayed parameters is at an alarm condition. In another embodiment, the alarm indicator 244 may indicate the status of the parameter displayed on the multi-mode display 206. In an embodiment, the speaker 236 may sound in conjunction with and/or in addition to the indicator 244. Moreover, in an embodiment, an alarming parameter may automatically be displayed, may be emphasized, flashed, colored, combinations of the same or the like to draw a user's attention to the alarming parameter.

[0073] Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.

[0074] FIG. 3 illustrates an exemplary display of the patient monitor 200. As shown in FIG. 3, the display includes the multi-mode display 206, the pulse rate display 216, parameter indicators 208, 210, the HbCO bar 212 and indicator 204, the PI™ bar 240, and the alarm indicator 244. In an embodiment, the multi-mode display 206 and the pulse rate display 216 each comprise a plurality of seven segment displays 302 capable of displaying alpha-numeric information. As disclosed in the foregoing, the exemplary display may advantageously include color-coded parameter displays. Moreover, the exemplary display may include color progressions, flashing, flashing progressions, audible alarms, audible progressions, or the like, indicating worsening measured values of physiological data. In addition, in an embodiment, some or all of the displays may flash at a first rate to indicate attempts to acquire data when actual measured values are unavailable. Moreover, some or all of the display may flash at a second rate to indicate low signal quality where confidence is decreasing that the measured values reflect actual physiological conditions.

[0075] FIG. 4 illustrates the display of FIG. 3 showing measured values of SpO₂, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 4, the multi-mode display 206 is displaying a percentage value of SpO₂, and the pulse rate display 216 is displaying a pulse rate in beats per minute. Accordingly, the parameter indicator 210 is activated to confirm the display of measured values of SpO₂. As disclosed in the foregoing, in an embodiment, the multi-mode display 206 is red, indicating blood oxygen measurements while the pulse rate display 216 is green, indicating normal values of a patient's pulse.

[0076] FIG. 4 also shows the PI™ bar 240 almost fully activated, representing good perfusion. In addition, the HbCO indicator 204 is showing communication with a sensor producing insufficient data to determine measured values of additional parameters, such as, HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about two (2) different wavelengths, may comprise sensors with insufficient data stored on a memory associated therewith, or the like.

[0077] FIG. 5 illustrates the display of FIG. 3 showing measured values of HbCO, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 5, the multi-mode display 206 is displaying a percentage value of HbCO, and the pulse rate display 216 is displaying an appropriate message indicating the HbCO measurement, such as, for example, “CO”. Also, the multi-mode display 206 has shifted the data to the left to quickly and efficiently indicate that the displayed parameter is other than SpO₂. Accordingly, the parameter indicator 208 is also activated to confirm the display of measured values of HbCO. As disclosed in the foregoing, in an embodiment, the multi-mode display 206 and pulse rate display message 216 are orange.

[0078] FIG. 5 also shows the PI™ bar 240 almost fully activated, representing good perfusion. In addition, the activation of the HbCO indicator 204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about eight (8) or more different wavelengths; however, such sensors may comprise about two (2) or more different wavelengths. Moreover, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 5 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 212 and multi-mode display 206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 244 is also activated, and in some embodiments, the speaker 236 as well.

[0079] FIG. 6 illustrates the display of FIG. 3 showing measured values of SpO₂, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. In contrast to FIG. 4, FIG. 6 shows that the monitor 200 is communicating with a sensor capable of producing sufficient data to determine measured values of HbCO, even though the displayed values are that of SpO₂and BPM. Thus, FIG. 6 shows the activation of the HbCO indicator 204, and the continuous monitoring of HbCO by the HbCO bar 212. FIG. 6 also shows a high value of HbCO, and therefore, the indication of an alarm condition by activation of the alarm indicator 244. In an embodiment, upon determination of an alarm condition on a nondisplayed parameter, the monitor 200 may advantageously provide an alarm indication through speaker and alarm indicator activation, automatic toggle to the nondisplayed parameter on the multi-mode display 206 for a defined or undefined time, or the like.

[0080] FIG. 7 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor 700 capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 1. Patient monitors exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name “Rad 57 cm.” As shown in FIG. 7, the monitor 700 comprises a monitor similar to monitor 200 disclosed with reference to FIG. 2. Moreover, monitor 700 further includes a multi-mode display 706 capable of displaying, for example, measurements of HbMet and BPM. In an embodiment, the display 706 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 700. Thus, the multi-mode display 706 may advantageously cycle through two or more measured parameters. In such embodiments, the monitor 700 may also advantageously include parameter indicators 708, 710, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display 706 may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 706 displays measured values of BPM that are normal, the numbers may advantageously appear in green, while normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 706 may flash at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.

[0081] FIG. 7 also illustrates the monitor 700 comprising user input keys 718, including an HbCO/HbMet button 220. In an embodiment, activation of the HbCO/HbMet button 720 toggles the measured value displayed in the multi-mode display 706. For example, activation of the HbCO/HbMet button 720 toggles the multi-mode display 206 from displaying measured values of SpO₂and BPM, to HbCO and HbMet for about ten (10) seconds. Activation of the mode/enter button 222 or the next button 224 during the ten (10) second period returns the multi-mode display 706 back to SpO₂and BPM. A skilled artisan will also recognize that activation of the HbCO/HbMet button 720 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO₂and BPM, may remain displayed until further activation of the button 720, or the like.

[0082] The monitor 700 also comprises a coarser indication of HbMet through an HbMet bar 740. In an embodiment, a plurality of LED's activate from a bottom toward a top such that the bar “fills” to a level proportional to the measured value, with increments at about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, about 15% and greater than about 20%, although an artisan will recognize from the disclosure herein other useful delineations. Additionally, the HbMet bar 740 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.

[0083] Although disclosed with reference to the HbMet bar 740, and artisan will recognize from the disclosure herein other coarse or even gross indications of HbMet, or any measured parameter. For example, a single LED may advantageously show green, yellow, and red, to indicate worsening coarse values of HbMet. Alternatively, a single LED may simply light to indicate an alarm or approaching alarm condition.

[0084] FIG. 8 illustrates an exemplary display of the patient monitor 700 of FIG. 7. As shown in FIG. 8, the display includes the multi-mode displays 206, 706, parameter indicators 208, 210, 708, 710, the HbCO bar 212 and indicator 204, the HbMet bar 740, and the alarm indicator 244. In an embodiment, the multi-mode display 706 is similar to multi-mode display 206, comprising a plurality of seven segment displays 302 capable of displaying alpha-numeric information, and capable of altering its display characteristics or aspects in a wide variety of configurations discussed with reference to the display 206.

[0085] FIG. 9 illustrates the display of FIG. 8 showing measured values of SpO₂, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1. FIG. 9 also shows the HbMet bar 740 near the bottom and corresponding to about 1%, representing acceptable HbMet, while the HbCO bar 212 hovers at a dangerous near 20%. In addition, the HbCO indicator 204 is showing communication with a sensor producing sufficient data to determine measured values of additional parameters, such as, HbMet, HbCO or the like. In an embodiment, such sensors may comprise sensors capable of emitting light of more than two (2) different wavelengths, preferably more than four (4) different wavelengths, and more preferably eight (8) or more different wavelengths.

[0086] FIG. 10 illustrates the display of FIG. 8 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 10, the multi-mode display 706 is displaying a percentage value of HbMet that is shifted using the parameter indicator 708. The data has been advantageously shifted to the left to quickly and efficiently indicate that the displayed parameter is other than BPM. Accordingly, the parameter indicator 708 is also activated to confirm the display of measured values of HbMet. As disclosed in the foregoing, in an embodiment, the multi-mode display 706 is blue.

[0087] FIG. 10 also shows the HbMet bar 740 nearly empty, representing acceptable HbMet. In addition, the activation of the HbCO indicator 204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 10 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 212 and multi-mode display 206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 244 is also activated, and in some embodiments, the speaker 236 as well.

[0088] FIG. 11A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor 1100, such as, for example, the patient monitor of FIG. 1. Moreover, FIGS. 11B-11E illustrate exemplary display screens of the patient monitor of FIG. 11A. As shown in FIGS. 11A-11B, an embodiment of the monitor 1100 includes a display 1101 showing a plurality of parameter data. For example, the display may advantageously comprise a CRT or an LCD display including circuitry similar to that available on oximeters commercially available from Masimo Corporation of Irvine, Calif. sold under the name Radical™, and disclosed in the U.S. patents referenced above and incorporated above. However, an artisan will recognize from the disclosure herein many commercially available display components capable of displaying multiple parameter data along with the ability to display graphical data such as plethysmographs, trend traces, and the like.

[0089] In an embodiment, the display includes a measured value of SpO₂1102, a measured value of pulse rate 1104 in BPM, a plethysmograph 1106, a measured value of HbCO 1108, a measured value of HbMet 1110, a measured value of a perfusion quality 1112, a measured value of Hbt 1114, and a derived value of fractional saturation “SpaO₂” 116. In an embodiment, SpaO₂comprises HbO₂expressed as a percentage of the four main hemoglobin species, i.e., HbO₂, Hb, HbCO, and HbMet.

[0090] In an embodiment, one or more of the foregoing parameter includes trending or prediction indicators 1118 showing the current trend or prediction for that corresponding parameter. In an embodiment, the indicators 1118 may advantageously comprise an up arrow, a down arrow, and a hyphen bar to indicate up trending/prediction, down trending/prediction, or neutral trending/prediction.

[0091] FIG. 11C illustrates an exemplary display screen showing trend graph 1140 including trend line 1142 for HbMet. In an embodiment, the trend line 1142 may be advantageously colored for quick straightforward recognition of the trending parameter, may be associated with any one or more of the foregoing alarm attributes, may include trending lines for other parameters, or the like. The display screen also shows trending directional indicators 1142, 1144 for many of the displayed physiological parameters. In an embodiment, the directional indicators 1142, 1144 may advantageously comprises arrows showing the recent trend, predicted trend, user-customizable trend, combinations thereof, or the like for the associated parameters. In an embodiment, the directional indicators 1142, 1144 comprises an up arrow indicating a rising trend/predicted trend, a middle bar indicating a somewhat stable trend/predicted trend, and a down arrow indicating a lowering trend/predicted trend. An artisan will recognize a wide variety of other directional indicators 1142, 1144 from the disclosure herein.

[0092] FIG. 11D shows an exemplary display screen in vertical format. Such vertical format could be user actuated or based on a gravity switch. FIGS. 11E-11F illustrate additional displays of various physiological parameters similar to those discussed in the foregoing. being As shown in FIG. 11G, the display includes a measured value of SpO₂1162, a measured value of pulse rate 1164 in BPM, a plethysmograph 1166, a HbCO bar 1168, and a HbMet bar 1170. In an embodiment, the HbCO bar 1168 and HbMet bar 1170 may advantageously behave the same or similarly to the HbCO bar 212 and HbMet bar 712. Moreover, similar bars may advantageously display any of the physiological parameters discussed herein using display indicia appropriate to that parameter. For example, a SpO₂or SpaO₂bar may advantageously range from about 0% to about 100%, and more preferably range from about 50% to about 100%, while a Hbt bar may advantageously range from about 0 to about 30.

[0093] Moreover, similar to the disclosure above, the measured value of SpO₂1162 may advantageously toggle to measured values of HbCO, HbMet, Hbt, or the like based on, for example, actuation of user input keys, or the like.

[0094] In addition to the foregoing, the display may also include graphical data showing one or more color-coded or other identifying indicia for traces of trend data. Moreover, other graphical presentations may advantageously provide readily identifiable indications of monitored parameters or combinations of monitored parameters of the patient. For example, in an embodiment, the display includes a SpaO₂graph 1172. The SpaO₂graph 1172 plots SpO₂as a function of other blood analytes (1-SpaO₂), where SpaO₂comprises HbO₂expressed as a percentage of the four main hemoglobin species, i.e., HbO₂, Hb, HbCO, and HbMet. Thus, as shown in FIG. 11C, as the slope of the displayed line or arrow increases, the caregiver can readily note that the majority of hemoglobin carriers are being used to carry oxygen, and not, for example, harmful carbon monoxide. On the other hand, as the slope decreases, the caregiver can readily and advantageously note that the number of hemoglobin species available to carry oxygen is decreasing, regardless of the current value of SpO₂. Moreover, the length of the arrow or line also provides an indication of wellness, e.g., the higher the line the more oxygen saturation, the lower the line, the more likely there may be desaturation event, or the like.

[0095] Thus, the SpaO₂graph 1172 provides the caregiver with the ability to recognize that even though the measured value of SpO₂may be within acceptable ranges, there are potentially an unacceptable number of hemoglobin carriers unavailable for carrying oxygen, and that other potential problems may exist, such as, for example, harmful carbon monoxide levels, or the like. In an embodiment, various alarm conditions may cause the graph 1172 to change color, flash, or any combination of alarm indications discussed in the forgoing. Moreover, FIG. 11I illustrates yet an additional display of the foregoing parameters.

[0096] An embodiment may also include the monitor 1100 advantageously defining regions of wellness/severity of the monitored patient. For example, because the graph 1172 comprises two dimensions, the monitor 1100 may advantageously define regions where the patient's measured physiological parameters are considered acceptable, regions where the patient is considered at risk, regions where the patient is critical, and the like. For example, one region of acceptability may include a high SpO₂and a low 1-SpaO₂, another region of risk may include a high SpO₂and a high 1-SpaO₂, and another critical region may include a low SpO₂and a high 1-SpaO₂. Moreover, an artisan will recognize from the disclosure herein that different parameters may also be combined to provide readily identifiable indications of patient wellness.

[0097] In addition to or as an alternative to the two dimensional SpaO₂graph 1172, the monitor 1100 may also include a three dimensional graph, such as, for example, extending the graph 1172 along the variable of time. In this embodiment, the forgoing regions advantageously become three dimensional surfaces of wellness. Moreover, trend data may also be advantageously added to the surface to provide a history of when particular monitored parameters dipped in and out of various surfaces of wellness, risk, criticality, or the like. Such trend data could be color-coded, text identified, or the like. An artisan will also recognize that such surfaces may be dynamic. For example, measurements of HbCO>about 5 may dictate that trend data showing SpO₂<about 90% should be considered critical; however, measurements of HbCO<about 5 may dictate only SpO₂<about 85% would be critical. Again, an artisan will recognize from the disclosure herein other parameter combinations to create a wide variety of wellness/critical regions or surfaces that provide readily available visual or audio indications of patient well being, trigger specific alarms, or the like.

[0098] Moreover, the monitor 1100 may advantageously employ enlargement or reorganization of parameter data based on, for example, the severity of the measurement. For example, the monitor 1100 may display values for HbCO in a small portion of the screen or in the background, and when HbCO begins to approach abnormal levels, the small portion may advantageously grown as severity increases, even in some embodiments to dominate the display. Such visual alarming can be combined with audio alarms such as announcements, alarms, rising frequencies, or the like, and other visual alarms such as flashing, coloration, or the like to assist a caregiver in noticing the increasing severity of a monitored parameter. In an embodiment, a location of the display of an alarming value is changed to be displayed in a larger display area, such as 1102, so as to be readily noticeable and its display values readily ascertainable.

[0099] Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 100 may advantageously be adapted to monitor or be included in a monitor capable of measuring physiological parameters other than those determined through absorption spectroscopy, such as, for example, blood pressure, ECG, EKG, respiratory rates, volumes, inputs for blood pressure sensors, acoustical sensors, and the like. Moreover, the monitor 100 may be adapted for wireless communication to and from the sensor 106, and/or to and from other monitoring devices, such as, for example, multi-parameter or legacy monitoring devices.

[0100] Also, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to the appended claims.

[0101] Additionally, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Claims

What is claimed is:

1. A method of graphically displaying a plurality of physiological measurements on a single display, the method comprising:

obtaining a first physiological measurement;

obtaining a second physiological measurement;

displaying an indication of the first physiological measurement on a first display area;

displaying an indication of the second physiological measurement on the first display area, wherein the first display area alternates between displaying the indication of the first physiological measurement and the indication of the second physiological measurement;

automatically switching between the indication of the first physiological measurement and the indication of the second physiological measurement without human intervention when a trend of either the first physiological measurement or the second physiological measurement indicate an alarm condition.

2. The method of claim 1, wherein the first physiological measurement is one of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

3. The method of claim 1, wherein the second physiological measurement is one of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

4. The method of claim 1, further comprising switching between the indication of the first physiological measurement and the indication of the second physiological measurement based on a user activated input.

5. The method of claim 1, wherein the indication of the first physiological measurement is an indication of the trend of the first physiological measurement.

6. The method of claim 1, further comprising changing a color of the displayed indication of the physiological measurement based on a severity of the alarm condition.

7. The method of claim 1, further comprising changing a size of the indication of the first physiological measurement based on a severity of the alarm condition.

8. A physiological measurement and display system comprising:

a physiological sensor including a plurality of light emitting elements and a detector, the physiological sensor configured to measure and indication of at least two physiological parameters of a patient;

one or more processors configured to determine at least two physiological parameter measurements using the measured indication from the physiological sensor;

a display, the display including a first display area, at least a portion of each of the at least two physiological parameter measurements are alternatively displayed in the same display area, wherein the physiological parameter displayed switches from a first parameter to a second parameter when a trend of the second parameter indicates a worsening condition of the patient.

9. The system of claim 8, wherein the at least two physiological measurements comprise one or more of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

10. The system of claim 8, wherein a color of the displayed physiological parameter measurement is changed based on a severity of the worsening condition of the patient.

11. The system of claim 8, wherein a size of the displayed physiological parameter measurement is changed based on a severity of the worsening condition of the patient.

12. A physiological parameter display system capable of receiving and displaying measurements, the system comprising:

a display configured to display a plurality of indications of physiological measurements of a patient; and

at least one processor configured to alternate displaying at least two different measurement indications of physiological parameters in the same display area of the display, the at least one processor configured to switch from displaying a first measurement indication to displaying a second measurement indication when the second measurement indication indicates a worsening state of a patient under measurement.

13. The system of claim 12, wherein the plurality of indications of physiological measurements of a patient comprise one or more of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

14. The system of claim 12, wherein a color of the displayed measurement indication is changed based on a severity of the worsening condition of the patient.

15. The system of claim 12, wherein a size of the displayed measurement indication is changed based on a severity of the worsening condition of the patient.

Patent Citations (622)

Patent	Date	Inventor	Cited By
US3910701(A)	1975-10-01	Henderson et al.	Applicant
US4051522(A)	1977-09-01	Healy	Applicant
US4085378(A)	1978-04-01	Ryan	Applicant
US4267844(A)	1981-05-01	Yamanishi	Applicant
US4531527(A)	1985-07-01	Reinhold, Jr. et al.	Applicant
US4623248(A)	1986-11-01	Sperinde	Applicant
US4653498(A)	1987-03-01	New	Applicant
US4655225(A)	1987-04-01	Dahne et al.	Applicant
US4685464(A)	1987-08-01	Goldberger et al.	Applicant
US4745398(A)	1988-05-01	Abel	Applicant
US4765340(A)	1988-08-01	Sakai	Applicant
US4800495(A)	1989-01-01	Smith	Applicant
US4802486(A)	1989-02-01	Goodman	Applicant
US4805623(A)	1989-02-01	Jobsis	Applicant
US4854328(A)	1989-08-01	Pollack	Applicant
US4863265(A)	1989-09-01	Flower et al.	Applicant
US4870588(A)	1989-09-01	Merhav	Applicant
US4911167(A)	1990-03-01	Corenman et al.	Applicant
US4934372(A)	1990-06-01	Corenman et al.	Applicant
US4938218(A)	1990-07-01	Goodman et al.	Applicant
US4942877(A)	1990-07-01	Sakai	Applicant
US4955379(A)	1990-09-01	Hall	Applicant
US4960128(A)	1990-10-01	Gordon et al.	Applicant
US4964408(A)	1990-10-01	Hink et al.	Applicant
US4965840(A)	1990-10-01	Subbarao	Applicant
US5003252(A)	1991-03-01	Nystrom	Applicant
US5025791(A)	1991-06-01	Niwa	Applicant
USRE33643(E)	1991-07-01	Isaacson	Applicant
US5028787(A)	1991-07-01	Rosenthal et al.	Applicant
US5041187(A)	1991-08-01	Hink et al.	Applicant
US5069213(A)	1991-12-01	Polczynski	Applicant
US5077476(A)	1991-12-01	Rosenthal	Applicant
US5137023(A)	1992-08-01	Mendelson et al.	Applicant
US5163438(A)	1992-11-01	Gordon et al.	Applicant
US5170791(A)	1992-12-01	Boos et al.	Applicant
US5188108(A)	1993-02-01	Secker	Applicant
US5189609(A)	1993-02-01	Tivig et al.	Applicant
US5190038(A)	1993-03-01	Polson	Applicant
US5193124(A)	1993-03-01	Subbarao	Applicant
US5218962(A)	1993-06-01	Mannheimer	Applicant
US5226053(A)	1993-07-01	Cho et al.	Applicant
US5226417(A)	1993-07-01	Swedlow	Applicant
US5246002(A)	1993-09-01	Prosser	Applicant
US5247931(A)	1993-09-01	Norwood	Applicant
US5259381(A)	1993-11-01	Cheung	Applicant
US5270942(A)	1993-12-01	Reed	Applicant
US5307284(A)	1994-04-01	Brunfeldt	Applicant
US5319355(A)	1994-06-01	Russek	Applicant
US5331394(A)	1994-07-01	Shalon et al.	Applicant
US5337744(A)	1994-08-01	Branigan	Applicant
US5337745(A)	1994-08-01	Benaron	Applicant
US5341805(A)	1994-08-01	Stavridi et al.	Applicant
US5345510(A)	1994-09-01	Singhi	Applicant
US5353356(A)	1994-10-01	Waugh et al.	Applicant
US5355882(A)	1994-10-01	Ukawa et al.	Applicant
US5357965(A)	1994-10-01	Hall et al.	Applicant
US5368224(A)	1994-11-01	Richardson	Applicant
USD353195(S)	1994-12-01	Savage et al.	Applicant
USD353196(S)	1994-12-01	Savage et al.	Applicant
US5377676(A)	1995-01-01	Vari et al.	Applicant
US5384451(A)	1995-01-01	Smith et al.	Applicant
US5398003(A)	1995-03-01	Heyl et al.	Applicant
US5404003(A)	1995-04-01	Smith	Applicant
US5406952(A)	1995-04-01	Barnes	Applicant
USD359546(S)	1995-06-01	Savage et al.	Applicant
US5421329(A)	1995-06-01	Casciani	Applicant
US5431170(A)	1995-07-01	Mathews	Applicant
USD361840(S)	1995-08-01	Savage et al.	Applicant
US5438983(A)	1995-08-01	Flacone	Applicant
US5442940(A)	1995-08-01	Secker et al.	Applicant
USD362063(S)	1995-09-01	Savage et al.	Applicant
US5448991(A)	1995-09-01	Polson	Applicant
US5452717(A)	1995-09-01	Branigan et al.	Applicant
USD363120(S)	1995-10-01	Savage et al.	Applicant
US5456252(A)	1995-10-01	Vari et al.	Applicant
US5479934(A)	1996-01-01	Imran	Applicant
US5481620(A)	1996-01-01	Vaidyanathan	Applicant
US5482036(A)	1996-01-01	Diab et al.	Applicant
US5490505(A)	1996-02-01	Diab et al.	Applicant
US5494043(A)	1996-02-01	O'Sullivan et al.	Applicant
US5503148(A)	1996-04-01	Pologe	Applicant
US5533511(A)	1996-07-01	Kaspari et al.	Applicant
US5534851(A)	1996-07-01	Russek	Applicant
US5542421(A)	1996-08-01	Erdman	Applicant
US5549111(A)	1996-08-01	Wright et al.	Applicant
US5561275(A)	1996-10-01	Savage et al.	Applicant
US5562002(A)	1996-10-01	Lalin	Applicant
US5575284(A)	1996-11-01	Athan et al.	Applicant
US5588435(A)	1996-12-01	Weng et al.	Applicant
US5590649(A)	1997-01-01	Caro et al.	Applicant
US5602924(A)	1997-02-01	Durand et al.	Applicant
US5608820(A)	1997-03-01	Vaidyanathan	Applicant
US5610996(A)	1997-03-01	Eller	Applicant
US5632272(A)	1997-05-01	Diab et al.	Applicant
US5638816(A)	1997-06-01	Kiani-Azarbayjany et al.	Applicant
US5638818(A)	1997-06-01	Diab et al.	Applicant
US5645440(A)	1997-07-01	Tobler et al.	Applicant
US5652566(A)	1997-07-01	Lambert	Applicant
US5685299(A)	1997-11-01	Diab et al.	Applicant
US5719589(A)	1998-02-01	Norman et al.	Applicant
US5720284(A)	1998-02-01	Aoyagi et al.	Applicant
US5720293(A)	1998-02-01	Quinn	Applicant
USD393830(S)	1998-04-01	Tobler et al.	Applicant
US5743262(A)	1998-04-01	Lepper, Jr. et al.	Applicant
US5758644(A)	1998-06-01	Diab et al.	Applicant
US5760910(A)	1998-06-01	Lepper, Jr. et al.	Applicant
US5769785(A)	1998-06-01	Diab et al.	Applicant
US5782237(A)	1998-07-01	Casciani	Applicant
US5782757(A)	1998-07-01	Diab et al.	Applicant
US5785659(A)	1998-07-01	Caro et al.	Applicant
US5791347(A)	1998-08-01	Flaherty et al.	Applicant
US5810734(A)	1998-09-01	Caro et al.	Applicant
US5820267(A)	1998-10-01	Bryars	Applicant
US5823950(A)	1998-10-01	Diab et al.	Applicant
US5830131(A)	1998-11-01	Caro et al.	Applicant
US5833618(A)	1998-11-01	Caro et al.	Applicant
US5842979(A)	1998-12-01	Jarman	Applicant
US5853364(A)	1998-12-01	Baker, Jr. et al.	Applicant
US5860919(A)	1999-01-01	Kiani-Azarbayjany et al.	Applicant
US5865736(A)	1999-02-01	Baker, Jr. et al.	Applicant
US5890929(A)	1999-04-01	Mills et al.	Applicant
US5891022(A)	1999-04-01	Pologe	Applicant
US5891023(A)	1999-04-01	Lynn	Applicant
US5904654(A)	1999-05-01	Wohltmann et al.	Applicant
US5919134(A)	1999-07-01	Diab	Applicant
US5921921(A)	1999-07-01	Potratz et al.	Applicant
US5934925(A)	1999-08-01	Tobler et al.	Applicant
US5940182(A)	1999-08-01	Lepper, Jr. et al.	Applicant
US5950139(A)	1999-09-01	Korycan	Applicant
US5987343(A)	1999-11-01	Kinast	Applicant
US5995855(A)	1999-11-01	Kiani et al.	Applicant
US5997343(A)	1999-12-01	Mills et al.	Applicant
US6002952(A)	1999-12-01	Diab et al.	Applicant
US6011986(A)	2000-01-01	Diab et al.	Applicant
US6027452(A)	2000-02-01	Flaherty et al.	Applicant
US6036642(A)	2000-03-01	Diab et al.	Applicant
US6045509(A)	2000-04-01	Caro et al.	Applicant
US6047203(A)	2000-04-01	Sackner et al.	Applicant
US6064910(A)	2000-05-01	Andersson et al.	Applicant
US6067462(A)	2000-05-01	Diab et al.	Applicant
US6081735(A)	2000-06-01	Diab et al.	Applicant
US6083172(A)	2000-07-01	Baker, Jr. et al.	Applicant
US6088607(A)	2000-07-01	Diab et al.	Applicant
US6110522(A)	2000-08-01	Lepper, Jr. et al.	Applicant
US6119026(A)	2000-09-01	McNulty et al.	Applicant
US6122535(A)	2000-09-01	Kaestle et al.	Applicant
US6124597(A)	2000-09-01	Shehada et al.	Applicant
US6128521(A)	2000-10-01	Marro et al.	Applicant
US6129675(A)	2000-10-01	Jay	Applicant
US6135952(A)	2000-10-01	Coetzee	Applicant
US6144868(A)	2000-11-01	Parker	Applicant
US6149588(A)	2000-11-01	Noda et al.	Applicant
US6151516(A)	2000-11-01	Kiani-Azarbayjany et al.	Applicant
US6152754(A)	2000-11-01	Gerhardt et al.	Applicant
US6157850(A)	2000-12-01	Diab et al.	Applicant
US6165005(A)	2000-12-01	Mills et al.	Applicant
US6174283(B1)	2001-01-01	Nevo et al.	Applicant
US6184521(B1)	2001-02-01	Coffin, IV et al.	Applicant
US6188407(B1)	2001-02-01	Smith et al.	Applicant
US6192261(B1)	2001-02-01	Gratton et al.	Applicant
US6206830(B1)	2001-03-01	Diab et al.	Applicant
US6229856(B1)	2001-05-01	Diab et al.	Applicant
US6232609(B1)	2001-05-01	Snyder et al.	Applicant
US6236872(B1)	2001-05-01	Diab et al.	Applicant
US6241683(B1)	2001-06-01	Macklem et al.	Applicant
US6253097(B1)	2001-06-01	Aronow et al.	Applicant
US6256523(B1)	2001-07-01	Diab et al.	Applicant
US6262698(B1)	2001-07-01	Blum	Applicant
US6263222(B1)	2001-07-01	Diab et al.	Applicant
US6278522(B1)	2001-08-01	Lepper, Jr. et al.	Applicant
US6280213(B1)	2001-08-01	Tobler et al.	Applicant
US6285895(B1)	2001-09-01	Ristolainen et al.	Applicant
US6285896(B1)	2001-09-01	Tobler et al.	Applicant
US6301493(B1)	2001-10-01	Marro et al.	Applicant
US6317627(B1)	2001-11-01	Ennen et al.	Applicant
US6321100(B1)	2001-11-01	Parker	Applicant
US6325761(B1)	2001-12-01	Jay	Applicant
US6334065(B1)	2001-12-01	Al-Ali et al.	Applicant
US6343224(B1)	2002-01-01	Parker	Applicant
US6349228(B1)	2002-02-01	Kiani et al.	Applicant
US6360113(B1)	2002-03-01	Dettling	Applicant
US6360114(B1)	2002-03-01	Diab et al.	Applicant
US6368283(B1)	2002-04-01	Xu et al.	Applicant
US6371921(B1)	2002-04-01	Caro et al.	Applicant
US6377829(B1)	2002-04-01	Al-Ali	Applicant
US6388240(B2)	2002-05-01	Schulz et al.	Applicant
US6397091(B2)	2002-05-01	Diab et al.	Applicant
US6430437(B1)	2002-08-01	Marro	Applicant
US6430525(B1)	2002-08-01	Weber et al.	Applicant
US6455340(B1)	2002-09-01	Chua et al.	Applicant
US6463311(B1)	2002-10-01	Diab	Applicant
US6466824(B1)	2002-10-01	Struble	Applicant
US6470199(B1)	2002-10-01	Kopotic et al.	Applicant
US6501975(B2)	2002-12-01	Diab et al.	Applicant
US6505059(B1)	2003-01-01	Kollias et al.	Applicant
US6505061(B2)	2003-01-01	Larson	Applicant
US6515273(B2)	2003-02-01	Al-Ali	Applicant
US6519486(B1)	2003-02-01	Edgar, Jr. et al.	Applicant
US6519487(B1)	2003-02-01	Parker	Applicant
US6525386(B1)	2003-02-01	Mills et al.	Applicant
US6526300(B1)	2003-02-01	Kiani et al.	Applicant
US6541756(B2)	2003-04-01	Schulz et al.	Applicant
US6542764(B1)	2003-04-01	Al-Ali et al.	Applicant
US6545652(B1)	2003-04-01	Tsuji	Applicant
US6580086(B1)	2003-06-01	Schulz et al.	Applicant
US6584336(B1)	2003-06-01	Ali et al.	Applicant
US6595316(B2)	2003-07-01	Cybulski et al.	Applicant
US6597932(B2)	2003-07-01	Tian et al.	Applicant
US6597933(B2)	2003-07-01	Kiani et al.	Applicant
US6606511(B1)	2003-08-01	Ali et al.	Applicant
US6632181(B2)	2003-10-01	Flaherty et al.	Applicant
US6639668(B1)	2003-10-01	Trepagnier	Applicant
US6640116(B2)	2003-10-01	Diab	Applicant
US6643530(B2)	2003-11-01	Diab et al.	Applicant
US6650917(B2)	2003-11-01	Diab et al.	Applicant
US6654624(B2)	2003-11-01	Diab et al.	Applicant
US6658276(B2)	2003-12-01	Kianl et al.	Applicant
US6661161(B1)	2003-12-01	Lanzo et al.	Applicant
US6671531(B2)	2003-12-01	Al-Ali et al.	Applicant
US6678543(B2)	2004-01-01	Diab et al.	Applicant
US6684090(B2)	2004-01-01	Ali et al.	Applicant
US6684091(B2)	2004-01-01	Parker	Applicant
US6690466(B2)	2004-02-01	Miller et al.	Applicant
US6697656(B1)	2004-02-01	Al-Ali	Applicant
US6697657(B1)	2004-02-01	Shehada et al.	Applicant
US6697658(B2)	2004-02-01	Al-Ali	Applicant
USRE38476(E)	2004-03-01	Diab et al.	Applicant
US6699194(B1)	2004-03-01	Diab et al.	Applicant
US6714804(B2)	2004-03-01	Al-Ali et al.	Applicant
USRE38492(E)	2004-04-01	Diab et al.	Applicant
US6721582(B2)	2004-04-01	Trepagnier et al.	Applicant
US6721585(B1)	2004-04-01	Parker	Applicant
US6725075(B2)	2004-04-01	Al-Ali	Applicant
US6728560(B2)	2004-04-01	Kollias et al.	Applicant
US6735459(B2)	2004-05-01	Parker	Applicant
US6743172(B1)	2004-06-01	Blike	Applicant
US6745060(B2)	2004-06-01	Diab et al.	Applicant
US6760607(B2)	2004-07-01	Al-Ali	Applicant
US6770028(B1)	2004-08-01	Ali et al.	Applicant
US6771994(B2)	2004-08-01	Kiani et al.	Applicant
US6792300(B1)	2004-09-01	Diab et al.	Applicant
US6800373(B2)	2004-10-01	Corczyca	Applicant
US6813511(B2)	2004-11-01	Diab et al.	Applicant
US6816741(B2)	2004-11-01	Diab	Applicant
US6822564(B2)	2004-11-01	Al-Ali	Applicant
US6826419(B2)	2004-11-01	Diab et al.	Applicant
US6829501(B2)	2004-12-01	Nielsen et al.	Applicant
US6830711(B2)	2004-12-01	Mills et al.	Applicant
US6850787(B2)	2005-02-01	Weber et al.	Applicant
US6850788(B2)	2005-02-01	Al-Ali	Applicant
US6852083(B2)	2005-02-01	Caro et al.	Applicant
US6861639(B2)	2005-03-01	Al-Ali	Applicant
US6861641(B1)	2005-03-01	Adams	Applicant
US6898452(B2)	2005-05-01	Al-Ali et al.	Applicant
US6920345(B2)	2005-07-01	Al-Ali et al.	Applicant
US6931268(B1)	2005-08-01	Kiani-Azarbayjany et al.	Applicant
US6934570(B2)	2005-08-01	Kiani et al.	Applicant
US6939305(B2)	2005-09-01	Flaherty et al.	Applicant
US6943348(B1)	2005-09-01	Coffin, IV	Applicant
US6950687(B2)	2005-09-01	Al-Ali	Applicant
US6956572(B2)	2005-10-01	Zaleski	Applicant
US6961598(B2)	2005-11-01	Diab	Applicant
US6970792(B1)	2005-11-01	Diab	Applicant
US6979812(B2)	2005-12-01	Al-Ali	Applicant
US6985764(B2)	2006-01-01	Mason et al.	Applicant
US6993371(B2)	2006-01-01	Kiani et al.	Applicant
US6996427(B2)	2006-02-01	Ali et al.	Applicant
US6999904(B2)	2006-02-01	Weber et al.	Applicant
US7003338(B2)	2006-02-01	Weber et al.	Applicant
US7003339(B2)	2006-02-01	Diab et al.	Applicant
US7015451(B2)	2006-03-01	Dalke et al.	Applicant
US7024233(B2)	2006-04-01	Ali et al.	Applicant
US7027849(B2)	2006-04-01	Al-Ali	Applicant
US7030749(B2)	2006-04-01	Al-Ali	Applicant
US7039449(B2)	2006-05-01	Al-Ali	Applicant
US7041060(B2)	2006-05-01	Flaherty et al.	Applicant
US7044918(B2)	2006-05-01	Diab	Applicant
US7067893(B2)	2006-06-01	Mills et al.	Applicant
US7096052(B2)	2006-08-01	Mason et al.	Applicant
US7096054(B2)	2006-08-01	Abdul-Hafiz et al.	Applicant
US7132641(B2)	2006-11-01	Schulz et al.	Applicant
US7142901(B2)	2006-11-01	Kiani et al.	Applicant
US7149561(B2)	2006-12-01	Diab	Applicant
US7186966(B2)	2007-03-01	Al-Ali	Applicant
US7190261(B2)	2007-03-01	Al-Ali	Applicant
US7215984(B2)	2007-05-01	Diab	Applicant
US7215986(B2)	2007-05-01	Diab	Applicant
US7221971(B2)	2007-05-01	Diab	Applicant
US7225006(B2)	2007-05-01	Al-Ali et al.	Applicant
US7225007(B2)	2007-05-01	Al-Ali	Applicant
USRE39672(E)	2007-06-01	Shehada et al.	Applicant
US7239905(B2)	2007-07-01	Kiani-Azarbayjany et al.	Applicant
US7245953(B1)	2007-07-01	Parker	Applicant
US7254429(B2)	2007-08-01	Schurman et al.	Applicant
US7254431(B2)	2007-08-01	Al-Ali et al.	Applicant
US7254433(B2)	2007-08-01	Diab et al.	Applicant
US7254434(B2)	2007-08-01	Schulz et al.	Applicant
US7272425(B2)	2007-09-01	Al-Ali	Applicant
US7274955(B2)	2007-09-01	Kiani et al.	Applicant
USD554263(S)	2007-10-01	Al-Ali	Applicant
US7280858(B2)	2007-10-01	Al-Ali et al.	Applicant
US7289835(B2)	2007-10-01	Mansfield et al.	Applicant
US7292883(B2)	2007-11-01	De Felice et al.	Applicant
US7295866(B2)	2007-11-01	Al-Ali	Applicant
US7299080(B2)	2007-11-01	Acosta et al.	Applicant
US7328053(B1)	2008-02-01	Diab et al.	Applicant
US7332784(B2)	2008-02-01	Mills et al.	Applicant
US7340287(B2)	2008-03-01	Mason et al.	Applicant
US7341559(B2)	2008-03-01	Schulz et al.	Applicant
US7343186(B2)	2008-03-01	Lamego et al.	Applicant
USD566282(S)	2008-04-01	Al-Ali et al.	Applicant
US7355512(B1)	2008-04-01	Al-Ali	Applicant
US7356365(B2)	2008-04-01	Schurman	Applicant
US7371981(B2)	2008-05-01	Abdul-Hafiz	Applicant
US7373193(B2)	2008-05-01	Al-Ali et al.	Applicant
US7373194(B2)	2008-05-01	Weber et al.	Applicant
US7376453(B1)	2008-05-01	Diab et al.	Applicant
US7377794(B2)	2008-05-01	Al-Ali et al.	Applicant
US7377899(B2)	2008-05-01	Weber et al.	Applicant
US7383070(B2)	2008-06-01	Diab et al.	Applicant
US7415297(B2)	2008-08-01	Al-Ali et al.	Applicant
US7428432(B2)	2008-09-01	Ali et al.	Applicant
US7438683(B2)	2008-10-01	Al-Ali et al.	Applicant
US7440786(B2)	2008-10-01	Hockersmith et al.	Applicant
US7440787(B2)	2008-10-01	Diab	Applicant
US7454240(B2)	2008-11-01	Diab et al.	Applicant
US7467002(B2)	2008-12-01	Weber et al.	Applicant
US7469157(B2)	2008-12-01	Diab et al.	Applicant
US7471969(B2)	2008-12-01	Diab et al.	Applicant
US7471971(B2)	2008-12-01	Diab et al.	Applicant
US7483729(B2)	2009-01-01	Al-Ali et al.	Applicant
US7483730(B2)	2009-01-01	Diab et al.	Applicant
US7489958(B2)	2009-02-01	Diab et al.	Applicant
US7496391(B2)	2009-02-01	Diab et al.	Applicant
US7496393(B2)	2009-02-01	Diab et al.	Applicant
USD587657(S)	2009-03-01	Al-Ali et al.	Applicant
US7499741(B2)	2009-03-01	Diab et al.	Applicant
US7499835(B2)	2009-03-01	Weber et al.	Applicant
US7500950(B2)	2009-03-01	Al-Ali et al.	Applicant
US7509154(B2)	2009-03-01	Diab et al.	Applicant
US7509494(B2)	2009-03-01	Al-Ali	Applicant
US7510849(B2)	2009-03-01	Schurman et al.	Applicant
US7526328(B2)	2009-04-01	Diab et al.	Applicant
US7530942(B1)	2009-05-01	Diab	Applicant
US7530949(B2)	2009-05-01	Al Ali et al.	Applicant
US7530955(B2)	2009-05-01	Diab et al.	Applicant
US7563110(B2)	2009-07-01	Al-Ali et al.	Applicant
US7596398(B2)	2009-09-01	Al-Ali et al.	Applicant
US7618375(B2)	2009-11-01	Flaherty	Applicant
USD606659(S)	2009-12-01	Kiani et al.	Applicant
US7647083(B2)	2010-01-01	Al-Ali et al.	Applicant
USD609193(S)	2010-02-01	Al-Ali et al.	Applicant
USD614305(S)	2010-04-01	Al-Ali et al.	Applicant
USRE41317(E)	2010-05-01	Parker	Applicant
US7729733(B2)	2010-06-01	Al-Ali et al.	Applicant
US7734320(B2)	2010-06-01	Al-Ali	Applicant
US7735729(B2)	2010-06-01	Rowe et al.	Applicant
US7761127(B2)	2010-07-01	Al-Ali et al.	Applicant
US7761128(B2)	2010-07-01	Al-Ali et al.	Applicant
US7764982(B2)	2010-07-01	Dalke et al.	Applicant
USD621516(S)	2010-08-01	Kiani et al.	Applicant
US7791155(B2)	2010-09-01	Diab	Applicant
US7801581(B2)	2010-09-01	Diab	Applicant
US7822452(B2)	2010-10-01	Schurman et al.	Applicant
USRE41912(E)	2010-11-01	Parker	Applicant
US7844313(B2)	2010-11-01	Kiani et al.	Applicant
US7844314(B2)	2010-11-01	Al-Ali	Applicant
US7844315(B2)	2010-11-01	Al-Ali	Applicant
US7865222(B2)	2011-01-01	Weber et al.	Applicant
US7873497(B2)	2011-01-01	Weber et al.	Applicant
US7880606(B2)	2011-02-01	Al-Ali	Applicant
US7880626(B2)	2011-02-01	Al-Ali et al.	Applicant
US7891355(B2)	2011-02-01	Al-Ali et al.	Applicant
US7894868(B2)	2011-02-01	Al-Ali et al.	Applicant
US7899507(B2)	2011-03-01	Al-Ali et al.	Applicant
US7899518(B2)	2011-03-01	Trepagnier et al.	Applicant
US7904132(B2)	2011-03-01	Weber et al.	Applicant
US7909772(B2)	2011-03-01	Popov et al.	Applicant
US7910875(B2)	2011-03-01	Al-Ali	Applicant
US7919713(B2)	2011-04-01	Al-Ali et al.	Applicant
US7937128(B2)	2011-05-01	Al-Ali	Applicant
US7937129(B2)	2011-05-01	Mason et al.	Applicant
US7937130(B2)	2011-05-01	Diab et al.	Applicant
US7941199(B2)	2011-05-01	Kiani	Applicant
US7951086(B2)	2011-05-01	Flaherty et al.	Applicant
US7957780(B2)	2011-06-01	Lamego et al.	Applicant
US7962188(B2)	2011-06-01	Kiani et al.	Applicant
US7962190(B1)	2011-06-01	Diab et al.	Applicant
US7976472(B2)	2011-07-01	Kiani	Applicant
US7988637(B2)	2011-08-01	Diab	Applicant
US7990382(B2)	2011-08-01	Kiani	Applicant
US7991446(B2)	2011-08-01	Ali et al.	Applicant
US8000761(B2)	2011-08-01	Al-Ali	Applicant
US8008088(B2)	2011-08-01	Bellott et al.	Applicant
USRE42753(E)	2011-09-01	Kiani-Azarbayjany et al.	Applicant
US8019400(B2)	2011-09-01	Diab et al.	Applicant
US8028701(B2)	2011-10-01	Al-Ali et al.	Applicant
US8029765(B2)	2011-10-01	Bellott et al.	Applicant
US8036728(B2)	2011-10-01	Diab et al.	Applicant
US8046040(B2)	2011-10-01	Ali et al.	Applicant
US8046041(B2)	2011-10-01	Diab et al.	Applicant
US8046042(B2)	2011-10-01	Diab et al.	Applicant
US8048040(B2)	2011-11-01	Kiani	Applicant
US8050728(B2)	2011-11-01	Al-Ali et al.	Applicant
USRE43169(E)	2012-02-01	Parker	Applicant
US8118620(B2)	2012-02-01	Al-Ali et al.	Applicant
US8126528(B2)	2012-02-01	Diab et al.	Applicant
US8128572(B2)	2012-03-01	Diab et al.	Applicant
US8130105(B2)	2012-03-01	Al-Ali et al.	Applicant
US8145287(B2)	2012-03-01	Diab et al.	Applicant
US8150487(B2)	2012-04-01	Diab et al.	Applicant
US8175672(B2)	2012-05-01	Parker	Applicant
US8180420(B2)	2012-05-01	Diab et al.	Applicant
US8182443(B1)	2012-05-01	Kiani	Applicant
US8185180(B2)	2012-05-01	Diab et al.	Applicant
US8190223(B2)	2012-05-01	Al-Ali et al.	Applicant
US8190227(B2)	2012-05-01	Diab et al.	Applicant
US8203438(B2)	2012-06-01	Kiani et al.	Applicant
US8203704(B2)	2012-06-01	Merritt et al.	Applicant
US8224411(B2)	2012-07-01	Al-Ali et al.	Applicant
US8228181(B2)	2012-07-01	Al-Ali	Applicant
US8229533(B2)	2012-07-01	Diab et al.	Applicant
US8233955(B2)	2012-07-01	Al-Ali et al.	Applicant
US8244325(B2)	2012-08-01	Al-Ali et al.	Applicant
US8255026(B1)	2012-08-01	Al-Ali	Applicant
US8255027(B2)	2012-08-01	Al-Ali et al.	Applicant
US8255028(B2)	2012-08-01	Al-Ali et al.	Applicant
US8260577(B2)	2012-09-01	Weber et al.	Applicant
US8265723(B1)	2012-09-01	McHale et al.	Applicant
US8274360(B2)	2012-09-01	Sampath et al.	Applicant
US8301217(B2)	2012-10-01	Al-Ali et al.	Applicant
US8310336(B2)	2012-11-01	Muhsin et al.	Applicant
US8315683(B2)	2012-11-01	Al-Ali et al.	Applicant
USRE43860(E)	2012-12-01	Parker	Applicant
US8337403(B2)	2012-12-01	Al-Ali et al.	Applicant
US8346330(B2)	2013-01-01	Lamego	Applicant
US8353842(B2)	2013-01-01	Al-Ali et al.	Applicant
US8355766(B2)	2013-01-01	MacNeish, III et al.	Applicant
US8359080(B2)	2013-01-01	Diab et al.	Applicant
US8364223(B2)	2013-01-01	Al-Ali et al.	Applicant
US8364226(B2)	2013-01-01	Diab et al.	Applicant
US8374665(B2)	2013-02-01	Lamego	Applicant
US8385995(B2)	2013-02-01	Al-Ali et al.	Applicant
US8385996(B2)	2013-02-01	Smith et al.	Applicant
US8388353(B2)	2013-03-01	Kiani et al.	Applicant
US8399822(B2)	2013-03-01	Al-Ali	Applicant
US8401602(B2)	2013-03-01	Kiani	Applicant
US8405608(B2)	2013-03-01	Al-Ali et al.	Applicant
US8414499(B2)	2013-04-01	Al-Ali et al.	Applicant
US8418524(B2)	2013-04-01	Al-Ali	Applicant
US8423106(B2)	2013-04-01	Lamego et al.	Applicant
US2001/0045532(A1)	2001-11-01	Schulz et al.	Applicant
US2002/0021269(A1)	2002-02-01	Rast	Applicant
US2002/0026107(A1)	2002-02-01	Kiani et al.	Applicant
US2002/0035318(A1)	2002-03-01	Mannheimer et al.	Applicant
US2002/0038078(A1)	2002-03-01	Ito	Applicant
US2002/0038081(A1)	2002-03-01	Fein et al.	Applicant
US2002/0059047(A1)	2002-05-01	Haaland	Applicant
US2002/0082488(A1)	2002-06-01	Al-Ali	Applicant
US2002/0095078(A1)	2002-07-01	Mannheimer et al.	Applicant
US2002/0111748(A1)	2002-08-01	Kobayashi et al.	Applicant
US2002/0115919(A1)	2002-08-01	Al-Ali	Applicant
US2002/0154665(A1)	2002-10-01	Funabashi et al.	Applicant
US2002/0156353(A1)	2002-10-01	Larson	Applicant
US2002/0159002(A1)	2002-10-01	Chang	Applicant
US2002/0161291(A1)	2002-10-01	Kianl	Applicant
US2002/0165440(A1)	2002-11-01	Mason et al.	Applicant
US2003/0000522(A1)	2003-01-01	Lynn	Applicant
US2003/0018241(A1)	2003-01-01	Mannheimer	Applicant
US2003/0045784(A1)	2003-03-01	Palatnik et al.	Applicant
US2003/0045785(A1)	2003-03-01	Diab et al.	Applicant
US2003/0049232(A1)	2003-03-01	Page et al.	Applicant
US2003/0073890(A1)	2003-04-01	Hanna	Applicant
US2003/0109775(A1)	2003-06-01	O'Neil et al.	Applicant
US2003/0116769(A1)	2003-06-01	Song et al.	Applicant
US2003/0117296(A1)	2003-06-01	Seely	Applicant
US2003/0120160(A1)	2003-06-01	Yarita	Applicant
US2003/0120164(A1)	2003-06-01	Nielsen	Applicant
US2003/0135099(A1)	2003-07-01	Al-Ali	Applicant
US2003/0139657(A1)	2003-07-01	Solenberger	Applicant
US2003/0160257(A1)	2003-08-01	Bader et al.	Applicant
US2003/0195402(A1)	2003-10-01	Fein et al.	Applicant
US2004/0006261(A1)	2004-01-01	Swedlow et al.	Applicant
US2004/0033618(A1)	2004-02-01	Haass et al.	Applicant
US2004/0034898(A1)	2004-02-01	Bruegl	Applicant
US2004/0059209(A1)	2004-03-01	Al-Ali et al.	Applicant
US2004/0064259(A1)	2004-04-01	Haaland et al.	Applicant
US2004/0081621(A1)	2004-04-01	Arndt et al.	Applicant
US2004/0092805(A1)	2004-05-01	Yarita	Applicant
US2004/0133087(A1)	2004-07-01	Ali et al.	Applicant
US2004/0138538(A1)	2004-07-01	Stetson	Applicant
US2004/0138540(A1)	2004-07-01	Baker, Jr. et al.	Applicant
US2004/0147822(A1)	2004-07-01	Al-Ali et al.	Applicant
US2004/0147823(A1)	2004-07-01	Kiani et al.	Applicant
US2004/0158132(A1)	2004-08-01	Zaleski	Applicant
US2004/0158134(A1)	2004-08-01	Diab et al.	Applicant
US2004/0158135(A1)	2004-08-01	Baker, Jr. et al.	Applicant
US2004/0162472(A1)	2004-08-01	Berson et al.	Applicant
US2004/0167382(A1)	2004-08-01	Gardner et al.	Applicant
US2004/0176670(A1)	2004-09-01	Takamura et al.	Applicant
US2004/0181134(A1)	2004-09-01	Baker, Jr. et al.	Applicant
US2004/0199063(A1)	2004-10-01	O'Neil et al.	Applicant
US2004/0204639(A1)	2004-10-01	Casciani et al.	Applicant
US2004/0204868(A1)	2004-10-01	Maynard et al.	Applicant
US2004/0229391(A1)	2004-11-01	Ohya et al.	Applicant
US2004/0262046(A1)	2004-12-01	Simon et al.	Applicant
US2004/0267103(A1)	2004-12-01	Li et al.	Applicant
US2004/0267140(A1)	2004-12-01	Ito et al.	Applicant
US2005/0043902(A1)	2005-02-01	Haaland et al.	Applicant
US2005/0049469(A1)	2005-03-01	Aoyagi et al.	Applicant
US2005/0054908(A1)	2005-03-01	Blank et al.	Applicant
US2005/0070773(A1)	2005-03-01	Chin et al.	Applicant
US2005/0070775(A1)	2005-03-01	Chin et al.	Applicant
US2005/0075546(A1)	2005-04-01	Samsoondar et al.	Applicant
US2005/0085704(A1)	2005-04-01	Schulz et al.	Applicant
US2005/0085735(A1)	2005-04-01	Baker, Jr. et al.	Applicant
US2005/0124871(A1)	2005-06-01	Baker, Jr. et al.	Applicant
US2005/0143634(A1)	2005-06-01	Baker, Jr. et al.	Applicant
US2005/0143943(A1)	2005-06-01	Brown	Applicant
US2005/0148834(A1)	2005-07-01	Hull et al.	Applicant
US2005/0184895(A1)	2005-08-01	Petersen et al.	Applicant
US2005/0187447(A1)	2005-08-01	Chew et al.	Applicant
US2005/0187448(A1)	2005-08-01	Petersen et al.	Applicant
US2005/0187449(A1)	2005-08-01	Chew et al.	Applicant
US2005/0187450(A1)	2005-08-01	Chew et al.	Applicant
US2005/0187452(A1)	2005-08-01	Petersen et al.	Applicant
US2005/0187453(A1)	2005-08-01	Petersen et al.	Applicant
US2005/0197549(A1)	2005-09-01	Baker, Jr.	Applicant
US2005/0197579(A1)	2005-09-01	Baker, Jr.	Applicant
US2005/0197793(A1)	2005-09-01	Baker, Jr.	Applicant
US2005/0203357(A1)	2005-09-01	Debreczeny et al.	Applicant
US2005/0209515(A1)	2005-09-01	Hockersmith et al.	Applicant
US2005/0228253(A1)	2005-10-01	Debreczeny	Applicant
US2005/0250997(A1)	2005-11-01	Takeda et al.	Applicant
US2006/0030764(A1)	2006-02-01	Porges et al.	Applicant
US2006/0210120(A1)	2006-09-01	Rowe et al.	Applicant
US2006/0211922(A1)	2006-09-01	Al-Ali et al.	Applicant
US2006/0211923(A1)	2006-09-01	Al-Ali et al.	Applicant
US2006/0211924(A1)	2006-09-01	Smith et al.	Applicant
US2006/0211925(A1)	2006-09-01	Lamego et al.	Applicant
US2006/0211932(A1)	2006-09-01	Al-Ali et al.	Applicant
US2006/0226992(A1)	2006-10-01	Al-Ali et al.	Applicant
US2006/0229509(A1)	2006-10-01	Al-Ali et al.	Applicant
US2006/0238358(A1)	2006-10-01	Al-Ali et al.	Applicant
US2006/0241358(A1)	2006-10-01	Al-Ali et al.	Applicant
US2006/0241363(A1)	2006-10-01	Al-Ali et al.	Applicant
US2011/0009719(A1)	2011-01-01	Al-Ali et al.	Applicant
US2011/0237914(A1)	2011-09-01	Lamego	Applicant
DE3328862(A1)	1985-02-01		Applicant
EP104771(B1)	1984-04-01		Applicant
EP352923(A1)	1990-01-01		Applicant
EP419223	1991-03-01		Applicant
EP569670	1993-02-01		Applicant
EP569670	1993-11-01		Applicant
EP645117(A)	1995-03-01		Applicant
EP659384	1995-06-01		Applicant
EP675541	1995-10-01		Applicant
EP1895892	2010-05-01		Applicant
EP2305104	2011-04-01		Applicant
JP61-28172	1986-02-01		Applicant
JP63-275327	1988-11-01		Applicant
JP64-500495	1989-02-01		Applicant
JP2-145457	1990-12-01		Applicant
JP5-207993	1993-08-01		Applicant
JP6-505903	1994-07-01		Applicant
JP6-237013	1994-08-01		Applicant
JP7-281618	1995-10-01		Applicant
JP7-325546	1995-12-01		Applicant
JP9-192120	1997-07-01		Applicant
JP10-216112	1998-08-01		Applicant
JP10-509352	1998-09-01		Applicant
JP10-269344	1998-10-01		Applicant
JP10-269344(A)	1998-10-01		Applicant
JP10-295676	1998-11-01		Applicant
JP10-305026	1998-11-01		Applicant
JP11-163412	1999-06-01		Applicant
JP11-164826	1999-06-01		Applicant
JP11-506834	1999-06-01		Applicant
JP11-183377	1999-07-01		Applicant
JP2000-116625	2000-04-01		Applicant
JP2002-516689	2002-06-01		Applicant
JP2002-228579	2002-08-01		Applicant
JP2002-525151	2002-08-01		Applicant
JP2002-315739	2002-10-01		Applicant
JP2003-507718	2003-02-01		Applicant
JP2003-084108	2003-03-01		Applicant
JP2003-521985	2003-07-01		Applicant
JP2004-070179	2004-03-01		Applicant
JP2004-226277	2004-08-01		Applicant
JP2004-296736	2004-10-01		Applicant
JP2004-532526	2004-10-01		Applicant
JP2004-327760	2004-11-01		Applicant
JP2005-501589	2005-01-01		Applicant
JP2005-253478	2005-09-01		Applicant
JP4879913	2011-12-01		Applicant
WO84/03032	1984-08-01		Applicant
WO88/01150	1988-02-01		Applicant
WO88/02020	1988-02-01		Applicant
WO92/11803	1992-07-01		Applicant
WO92/15955	1992-09-01		Applicant
WO92/16142	1992-10-01		Applicant
WO92/20273	1992-11-01		Applicant
WO95/16387	1995-06-01		Applicant
WO95/21567	1995-08-01		Applicant
WO96/13208	1996-05-01		Applicant
WO97/01985	1997-01-01		Applicant
WO98/43071	1998-10-01		Applicant
WO98-43071	1998-10-01		Applicant
WO/18290	2000-04-01		Applicant
WO/42911(A1)	2000-07-01		Applicant
WO1/13790	2001-03-01		Applicant
WO1/30414	2001-05-01		Applicant
WO1/058347	2001-08-01		Applicant
WO2/17780	2002-03-01		Applicant
WO2/26123	2002-04-01		Applicant
WO2/089664	2002-11-01		Applicant
WO3/020129	2003-03-01		Applicant
WO3-068060	2003-08-01		Applicant
WO3/068060	2003-08-01		Applicant
WO2004/034898	2004-04-01		Applicant
WO2005/011488	2005-02-01		Applicant
WO2006/094168	2006-09-01		Applicant

Non-Patent Literature (110)

Burritt, M.; Current Analytical Approaches to Measuring Blood Analytes; vol. 36; No. 8(B); 1990.Applicant
European Examination Report dated Apr. 1, 2010, re EP App. No. 08 744 412.1-2319.Applicant
European Examination Report dated Mar. 18, 2011, re EP App. No. 08 744 412.1-2319.Applicant
European Examination Report dated Sep. 2, 2010, re EP App. No. 08 744 412.1-2319.Applicant
European Extended Search Report re EPO App. No. 10162402.1, SR dated Aug. 9, 2010.Applicant
Hall J., “Near-Infrared Spectrophotometry: A New Dimension in Clinical Chemistry”, vol. 38; No. 9; 1992.Applicant
International Search Report dated Jan. 11, 2007, for PCT/US2006/007516, filed Mar. 1, 2006.Applicant
Japanese First Office Action (Notice of Reasons for Rejection), re JP App. No. 2007-558247, dated Jun. 28, 2011.Applicant
Japanese Office Action (Notice of Allowance), re JP App. No. 2007-558247, dated Oct. 24, 2011.Applicant
Japanese Office Action (Notice of Reasons for Rejection) re JP App. No. 2007-558246, dated Jun. 28, 2011.Applicant
Japanese Office Action (Notice of Reasons for Rejection), re JP App. No. 2007-558238, dated Jun. 28, 2011.Applicant
Japanese Office Action re JP Application No. 2007-558249, dated Jul. 13, 2011.Applicant
Japanese Office Action re JP Application No. 2007-558249, dated Nov. 8, 2011.Applicant
Japanese Office Action re JP Application No. JP 2007-558208, dated Aug. 23, 2011.Applicant
Japanese Office Action re Jp Application No. JP 2007-558248, dated Nov. 8, 2011.Applicant
Japanese Office Action re JP Application No. 2007-558209, dated Oct. 25, 2011.Applicant
Japanese Office Action re JP Application No. 2007-558245, dated Oct. 25, 2011.Applicant
Japanese Office Action, re JP Application No. 2007-558237, dated Aug. 1, 2011.Applicant
Kuenstner, et al., J. Todd; Measurement of Hemoglobin in Unlysed Blood by Near-Infrared Spectroscopy; vol. 48; No. 4, 1994.Applicant
Manzke, et al., B., Multi Wavelength Pulse OXimetry in the Measurement of Hemoglobin Fractions; vol. 2676, date unknown.Applicant
Naumenko, E. K.; Choice of Wavelengths for Stable Determination of Concentrations of Hemoglobin Derivatives from Absorption Spectra of Erythrocytes; vol. 63; No. 1; pp. 60-66 Jan.-Feb. 1996; Original article submitted Nov. 3, 1994.Applicant
Patent Cooperation Treaty (PCT) International Search Report; PCT-US 2006-007389; Date of Mailing Jul. 17, 2006; pp. 1-9.Applicant
PCT International Search Report; PCT/US2006/007506; Date of Mailing Jul. 17, 2006; pp. 1-10.Applicant
PCT Search Report of International Application No. PCT/US2008/058327, Mailing Date of Jun. 30, 2009, in 12 pages.Applicant
Schmitt, E., “Measurement of Blood Hematocrit by Dual-wavelength Near-IR Photoplethysmography”, Physiological Monitoring and Early Detection Diagnostic Methods, Proc. SPIE vol. 1641, p. 150-161, May 1992.Applicant
Schmitt, J.; Simple Photon Diffusion Anaylsis of the Effects of Multiple Scattering on Pulse Oximetry; Mar. 14, 1991; revised Aug. 30, 1991.Applicant
Schnapp, et al., L.M.; Pulse Oximetry. Uses and Abuses.; Chest 1990; 98; 1244-1250001 10.1378/Chest.98.5.1244.Applicant
Appendixes for Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012.Applicant
Blitt, Casey D., Monitoring in Anesthesia and Critical Care Medicine, (2d ed. 1990).Applicant
Boualem Boashash, Estimating and Interpreting the Instantaneous Frequency of a Signal-Part I: Fundamentals, Proceedings of the IEEE, vol. 80, No. 4 (Apr. 1992).Applicant
Boualem Boashash, Note on the Use of the Wigner Distribution for Time-Frequency Signal Analysis, IEEE Transactions on Acoustics, Speech, and Signal Processing, vol. 36, No. 9 (Sep. 1988).Applicant
Business Wire, “Mallinckrodt Announces the Nellcor N-395 Pulse Oximeter With Oxismart XL and SatSeconds,” Oct. 7, 1999.Applicant
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,632,272, Doc. 554, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 551, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 508, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 21, 2012.Applicant
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 7,215,984, Doc. 561, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Mohammed K. Diab in Support of Masimo's Oppositions to Defendants' Motions for Summary Judgment of Invalidity and Noninfringement of U.S. Patent Nos. 5,632,272 and 7,215,984, Doc. 563, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted).Applicant
Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, vol. 1, Doc. 556, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,632,272, Doc. 553, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 548, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Perry D. Oldham in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, vol. 2, Doc. 558, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Declaration of Perry D. Oldham in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 550, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted).Applicant
Defendants' Answer and Philips Electronics North America Corp.'s Counterclaims to Masimo's First Amended Complaint, Doc. 11, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Nov. 7, 2011.Applicant
Defendants' Answer and Philips Electronics North America Corp.'s Counterclaims to Masimo's Second Amended Complaint, Doc. 43, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated May 11, 2012.Applicant
Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 402, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.Applicant
Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 410, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.Applicant
Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 406, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.Applicant
Defendants' Objections to Magistrate Judge Thynge's Report and Recommendation Regarding Claim Construction, Doc. 218, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2011.Applicant
Edward Bedrosian, The Analytic Signal Representation of Modulating Waveforms (1962).Applicant
Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012.Applicant
Hanzo et al., “A Portable Multimedia Communicator Scheme”, Multimedia Technologies and Future Applications: Proceedings of the IEEE International Symposium (1994).Applicant
Maciej Niedzwiecki et al. “Smoothing of Discontinuous Signals: The Competitive Approach,” IEEE Transactions on Signal Processing, vol. 43, No. 1, Jan. 1995, pp. 1-13.Applicant
Masimo Corporation's Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 552, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Masimo Corporation's Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent. No. 7,215,984, Doc. 555, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).Applicant
Masimo Corporation's Answering Brief in Opposition to Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 549, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted).Applicant
Masimo Corporation's Objections to the Report and Recommendation Regarding Claim Construction, Doc. 219, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 8, 2011.Applicant
Masimo Corporation's Response to Defendants' Objections to the Report and Recommendation Regarding Claim Construction, Doc. 232, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv00080 (LPS/MPT) dated Mar. 24, 2011.Applicant
Masimo's Answer to Philips' Counterclaims to Masimo's Second Amended Complaint, Doc. 358, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Jun. 4, 2012.Applicant
Masimo's Answer to Philips' Counterclaims, Doc. 28, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Dec. 30, 2011.Applicant
Memorandum Order Adopting Report and Recommendation Regarding Claim Construction, Doc. 319, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Jan. 17, 2011.Applicant
Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 444, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted).Applicant
Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 445, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted).Applicant
Philip Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, Doc. 394, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.Applicant
Philip's Opening Brief in Support of Defendant's Motion for Summary Judgment of Invalidity and Nonnigringement of U.S. Patent No. 7,215,984, Doc. 442, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted).Applicant
Philips' Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 413, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.Applicant
Philips' Response to Masimo Corporation's Objections to the Report and Recommendation Regarding Claim Construction, Doc. 230, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 24, 2011.Applicant
Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 614, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv00080 (LPS/MPT) dated Oct. 26, 2012 (Redacted).Applicant
Reply Brief in Support of Defendants' Motion for Summary Judgment of invalidity and Noninfringement of U.S. Patent. No. 7,216,984, Doc. 609, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv00080 (LPS/MPT) dated Oct. 26, 2012. (Redacted).Applicant
Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 613, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012 (Redacted).Applicant
Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 610, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012. (Redacted).Applicant
Report and Recommendation Regarding Claim Construction, Doc. 210, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Feb. 18, 2011.Applicant
Revised Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012.Applicant
Rusch, “Master's Thesis,” Graduate School University of South Florida, Tampa, Florida (Dec. 1994).Applicant
Scharf, “Optimization of Portable Pulse Oximetry Through Fourier Analysis”.Applicant
Scharf, “Pulse Oximetry Through Spectral Analysis”.Applicant
Second Amended Complaint for Patent Infringement, Doc. 42, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Apr. 25, 2012.Applicant
Steven W. Smith, The Scientist and Engineer's Guide to Digital Signal Processing, § 8 (1st ed. 1997).Applicant
Supplemental Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 18, 2012.Applicant
U.S. Appl. No. 90/012,551, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 6,970,792, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,553, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,024,233, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,403, filed Jul. 23, 2012, requesting ex parte reexamination of Patent No. 6,263,222, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,409, filed Aug. 17, 2012, requesting ex parte reexamination of Patent No. 6.699,194, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,463, filed Sep. 5, 2012, requesting ex parte reexamination of of Patent No. 7,215,984, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,532, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,499,835, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,534, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,962,188, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,538, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,377,899, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,541, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,899,507, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,542, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 8,180,420, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,543, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 6,850,787, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,546, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,438,683, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,548, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,880,606, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,557, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 8,150,487, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,561, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 8,019400, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,562, filed Sep. 14, 2012 requesting ex parte reexamination of Patent No. 6,463,311, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,566, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 7,530,955, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,567, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 6,684,090, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,568, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 8,128,572, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012,699, filed Oct. 4, 2012, requesting ex parte reexamination of Patent No. 6,002,952, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 90/012.555, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,440,787, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.Applicant
U.S. Appl. No. 95/002,183, filed Sep. 12, 2012, requesting inter partes reexamination of Patent No. 7,530,955, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.913 and 35 U.S.C. § 311.Applicant
V. Ya. Volkov, “Enhancing the Reliability and Accuracy of Pulse Oximetry with a Built-In Expert System,” Biomedical Engineering, vol. 27, No. 3 (May-Jun. 1993) (translated from Russian).Applicant
V. Ya. Volkov, “Principles and Algroithms for Determining Blood Oxygenation Level by Pulse Oximetry,” Biomedical Engineering, vol. 27, No. 1 (Jan.-Feb. 1993) (translated from Russian).Applicant
Wukitsch, et al., “Knowing Your Monitoring Equipment,” Journal of Clinical Monitoring, vol. 4, No. 4 (Oct. 1998).Applicant
Burritt, Mary F.; Current Analytical Approaches to Measuring Blood Analytes; vol. 36; No. 8(B); 1990.Applicant
Hall, et al., Jeffrey W.; Near-Infrared Spectrophotometry: A New Dimension in Clinical Chemistry; vol. 38; No. 9; 1992.Applicant
International Search Report for PCT/US2006/007516, mailed on Jan. 11, 2007, in 4 pages.Applicant
Japanese First Office Action (Notice of Reasons for Rejection), re JP App. No. 2007-558207, dated Jun. 28, 2011.Applicant
PCT Search Report of International Application No. PCT/US2008/058327, Mailing Date of Aug. 12, 2008, in 6 pages.Applicant
Schmitt, Joseph M.; Simple Photon Diffusion Anaylsis of the Effects of Multiple Scattering on Pulse Oximetry; Mar. 14, 1991; revised Aug. 30, 1991.Applicant
Schmitt, Joseph M.; Zhou, Guan-Xiong; Miller, Justin, Measurement of Blood Hematocrit by Dual-Wavelength Near-Ir Photoplethysmography, Published May 1992, Proc. Spie vol. 1641, p. 150-161, Physiological Monitoring and Early Detection Diagnostic Methods, Thomas S. Mang; Ed. (Spie Homepage), in 12 Pages.Applicant